"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04542993","Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy","Reszinate","Recruiting","No Results Available","Covid19|SARS-CoV Infection","Dietary Supplement: Zinc Picolinate|Dietary Supplement: Resveratrol|Dietary Supplement: Zinc Picolinate Placebo|Dietary Supplement: Resveratrol Placebo","Reduction in SARS-CoV-2 Viral load|Reduction in Severity of COVID-19 Disease","Swedish Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","SHS KAPH NSWE 20090","September 8, 2020","September 2021","June 2022","September 9, 2020",,"October 19, 2020","Swedish Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04542993"
2,"NCT04343261","Convalescent Plasma in the Treatment of COVID 19",,"Completed","Has Results","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|COVID|Coronavirus","Biological: Convalescent Plasma","Mortality|Viral Load|Serum Antibody Titers","Saint Francis Care","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SFH-20-23","April 10, 2020","July 23, 2020","August 13, 2020","April 13, 2020","September 17, 2020","September 24, 2020","Trinity Health Of New England, Hartford, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/Prot_SAP_000.pdf|""Informed Consent Form: Donor Consent"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_001.pdf|""Informed Consent Form: Patient Consent"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04343261"
3,"NCT04498325","Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)","Safe and tolerable dose of NT-I7 (Phase I only)|Percent change in absolute lymphocyte count (ALC)|Change in SARS-CoV-2 viral load|COVID-19 Symptom severity as measured by WHO Ordinal Scale for clinical improvement|Time to resolution of COVID-19 symptoms|Incidence of treatment-emergent adverse events|Number of participants by PCR result status (positive or negative)","Washington University School of Medicine|NeoImmune Tech","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","202009065","October 31, 2020","July 31, 2021","July 31, 2021","August 4, 2020",,"September 30, 2020","Saint Louis University Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04498325"
4,"NCT04399889","hCT-MSCs for COVID19 ARDS",,"Recruiting","No Results Available","COVID|Corona Virus Infection|COVID19","Biological: human cord tissue mesenchymal stromal cells","Safety of the Investigational Product|Describe the potential for MSC therapy to favorably alter the course of COVID-ARDs","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00105410","June 18, 2020","April 1, 2021","July 31, 2021","May 22, 2020",,"June 22, 2020","Duke Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04399889"
5,"NCT04382625","Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial",,"Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine","Change from Baseline Oxygenation on Day 1 to Day 5|Change from Baseline Oxygenation at Day 5|Intensive Care length of stay|Required Mechanical Ventilation|Required Oxygen supplementation|Hospitalization length of Stay|Mortality|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTc","Kootenai Health|Washington State University","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18244","October 2020","January 1, 2022","June 1, 2022","May 11, 2020",,"September 2, 2020","Kootenai Health, Coeur d'Alene, Idaho, United States",,"https://ClinicalTrials.gov/show/NCT04382625"
6,"NCT04363866","A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Hydroxychloroquine|Drug: Placebo","Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale|Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5|Toxicity of Study Drug Assessed by Incidence of Adverse Events","Oregon Health and Science University|OHSU Knight Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY00021303","May 2020","December 2020","June 2021","April 27, 2020",,"April 27, 2020","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04363866"
7,"NCT04584684","Mouth Rinses for Inactivation of COVID-19","MOR","Not yet recruiting","No Results Available","Covid19|Coronavirus Infection|SARS-CoV-2 Infection","Drug: 1.5-2% w/v Hydrogen Peroxide|Drug: 0.12% Chlorhexidine Gluconate|Drug: 21% Ethanol plus essential oils|Drug: 1% w/v Povidone-iodide|Drug: 0.075% Cetylpyridinium Chloride|Other: Saline","Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 15 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 30 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 45 Minutes|Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 60 Minutes","University of North Carolina, Chapel Hill","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","20-2040","October 2020","September 2022","September 2023","October 14, 2020",,"October 14, 2020","General and Oral Health Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04584684"
8,"NCT04353271","Trial of Hydroxychloroquine In Covid-19 Kinetics","THICK","Terminated","No Results Available","Covid 19|Corona Virus Infection","Drug: Hydroxychloroquine|Other: Placebo","Percentage of virus free subjects|Disease severity|Incidence of hospitalization|Incidence of Death|Incidence of confirmed SARS-CoV-2 Detection|Incidence of all-cause study medication discontinuation or withdrawal|Immunity to Covid-19","University of South Alabama","All","19 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","[1582736-1]","April 17, 2020","July 8, 2020","July 8, 2020","April 20, 2020",,"August 20, 2020","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04353271"
9,"NCT04432272","ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)","ABACCuS","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections","Biological: COVID-19 convalescent plasma","Avoidance of intubation at 28 days (group A)|Mortality (group B)|Cardio-circulatory arrest|Patient Outcome at 28 days|Renal failure|Liver failure|Cytokine Storm|Respiratory support|Vasopressor medication support|Length of ICU length of stay|Intensive Care Unit (ICU) mortality|Hospital length of stay|Ventilator free days|Intubation duration|Readmission|Serum anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality (group A)|Time from Transfusion to end of ventilator support (group B)","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-198","July 16, 2020","June 2021","August 2021","June 16, 2020",,"August 21, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04432272"
10,"NCT04530539","The Effect of Melatonin and Vitamin C on COVID-19",,"Not yet recruiting","No Results Available","Covid19|SARS-CoV Infection","Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey","Symptom Severity|Symptom progression","Lancaster General Hospital","All","50 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","2020-68","September 18, 2020","September 1, 2021","December 1, 2021","August 28, 2020",,"September 16, 2020","Lancaster General Health, Lancaster, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04530539"
11,"NCT04376593","PET/CT Imaging in COVID-19 Patients",,"Enrolling by invitation","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: 18F-αvβ6-BP","Administration of 18F-αvβ6-BP|Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1592298","May 1, 2020","May 2021","May 2022","May 6, 2020",,"July 7, 2020","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04376593"
12,"NCT04328012","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","COVIDMED","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Losartan|Drug: Placebos","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","Bassett Healthcare|Reid Health|Goshen Health System","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1581969","April 6, 2020","January 1, 2021","April 1, 2021","March 31, 2020",,"August 20, 2020","Bassett Medical Center, Cooperstown, New York, United States",,"https://ClinicalTrials.gov/show/NCT04328012"
13,"NCT04359810","Plasma Therapy of COVID-19 in Critically Ill Patients",,"Recruiting","No Results Available","SARS-CoV Infection","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma)","Time to Improvement|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital 28-day Mortality Rate","Max R. O'Donnell|New York Blood Center|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAAS9924","April 21, 2020","December 2020","April 2021","April 24, 2020",,"April 30, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359810"
14,"NCT04383587","Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers",,"Completed","No Results Available","SARS-CoV 2|COVID-19","Other: Serologic testing","Prevalence of COVID19 Antibody Positivity|Ability to predict immune status/antibody positivity","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20-004054","May 6, 2020","July 1, 2020","July 31, 2020","May 12, 2020",,"September 1, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04383587"
15,"NCT04318444","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with symptomatic, lab-confirmed COVID-19.","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9676","March 29, 2020","March 2021","March 2022","March 24, 2020",,"April 27, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04318444"
16,"NCT04377672","Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)",,"Recruiting","No Results Available","Corona Virus Infection","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection","Johns Hopkins University","All","1 Month to 18 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00247557","May 28, 2020","May 28, 2021","May 28, 2022","May 6, 2020",,"June 2, 2020","Johns Hopkins Hospitals, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04377672"
17,"NCT04354831","A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: anti-SARS-CoV-2 convalescent plasma","Overall Mortality within 60 days|Length of ICU stay during current admission for COVID","Medical College of Wisconsin|Froedtert Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","131","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00037712","May 11, 2020","May 1, 2022","May 1, 2023","April 21, 2020",,"May 13, 2020","Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04354831"
18,"NCT04390503","Convalescent Plasma for COVID-19 Close Contacts",,"Recruiting","No Results Available","SARS-CoV 2|COVID-19","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)","Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AAAT0052","May 2020","April 2021","April 2021","May 15, 2020",,"May 15, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04390503"
19,"NCT04497389","Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients",,"Not yet recruiting","No Results Available","SARS CoV-2","Biological: Human Amniotic Fluid","C-reactive protein","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","132922","September 15, 2020","September 15, 2021","September 15, 2021","August 4, 2020",,"September 9, 2020","University of Utah Health, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04497389"
20,"NCT04338126","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","TCInpatient","Not yet recruiting","No Results Available","COVID19","Drug: Tranexamic acid|Drug: Placebo oral tablet","Admission to Intensive Care Unit","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID2","September 30, 2020","December 15, 2020","December 31, 2020","April 8, 2020",,"June 11, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338126"
21,"NCT04393948","Lung Irradiation for COVID-19 Pneumonia",,"Recruiting","No Results Available","SARS-CoV 2","Radiation: Phase 1|Radiation: Phase 2","Phase 1: Feasibility and safety of treating hospitalized patients with SARS-CoV-2 pneumonia with single or bilateral whole lung irradiation|Phase 2: Proportion with clinical improvement on a 7-point ordinal scale on day 4 after randomization|Improvement or worsening on the 7-point ordinal scale over additional intervals|Rate and duration of use of supplemental oxygen|Rate and duration of fever > 38ºC|Rate and duration of invasive mechanical ventilation|Duration of hospitalization|Proportion of participants with overall survival up to 30 days after randomization|Improvement in radiographic findings related to infection/inflammation; comparisons include on study versus baseline scans and irradiated vs. unirradiated lung in subjects randomized to receive single lung irradiation|Treatment-emergent adverse events","Brigham and Women's Hospital","All","40 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020P001494","June 2020","October 2020","November 2020","May 19, 2020",,"June 25, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04393948"
22,"NCT04385199","Convalescent Plasma for Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection|Coronavirus|COVID","Biological: Convalescent plasma","Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13807","May 4, 2020","August 1, 2020","August 1, 2020","May 12, 2020",,"May 12, 2020","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04385199"
23,"NCT04364802","COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","PIIPPI","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Povidone-Iodine Nasal Spray and Gargle","Percent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|PVP-I Ease of Use|PVP-I Comfort","Alexandra Kejner|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","58748","April 29, 2020","May 2021","May 2021","April 28, 2020",,"May 14, 2020","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04364802"
24,"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",,"Recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131618","March 20, 2020","March 20, 2021","March 20, 2021","March 24, 2020",,"April 17, 2020","University of Utah Health, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04319731"
25,"NCT04502472","Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","Inova-CCP","Recruiting","No Results Available","Covid-19","Biological: Convalescent plasma transfusion","Change is clinical status|Transfusion related events|SOFA score at days 0, 7, 14, 21, 28|Length of Hospital Stay|Supplemental oxygen|Mechanical Ventilation|Change in mechanical ventilation status|Mortality|Change in inflammatory markers","Inova Health Care Services","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inova COVID-19 CCP","June 6, 2020","December 31, 2021","December 31, 2021","August 6, 2020",,"August 6, 2020","Inova Fairfax Medical Campus, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04502472"
26,"NCT04374279","Trial to Promote Recovery From COVID-19 With Endocrine Therapy","RECOVER","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet","Percentage of participants who have clinical improvement at day 7 after randomization|All-cause mortality|Duration of hospitalization|Percentage of patients needing upgrade to the intermediate care unit (IMC)|Duration of IMC stay|Percentage of patients needing upgrade to the intensive care unit (ICU)|Duration of ICU stay|Number of participants requiring mechanical ventilation|Duration of mechanical ventilation|Number of participants experiencing adverse events","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV2003|IRB00249425","November 2020","November 2021","November 2021","May 5, 2020",,"October 5, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04374279"
27,"NCT04348500","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease",,"Active, not recruiting","No Results Available","COVID19","Drug: Clazakizumab","Evaluate the safety of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay|Reduced need for ventilation","Cedars-Sinai Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00000644","April 24, 2020","December 31, 2020","March 31, 2021","April 16, 2020",,"October 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04348500"
28,"NCT04347954","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2|Compliance with study drug administration|Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT)","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB-56134","August 15, 2020","December 2020","January 2021","April 15, 2020",,"September 21, 2020","Stanford Health Care, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04347954"
29,"NCT04489628","Tele-health Enabled Clinical Trial for COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV Infection","Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring","Patients requiring admission to the hospital or experiencing death","University Hospitals Cleveland Medical Center|Northwestern University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STUDY20200461","August 1, 2020","August 1, 2021","August 1, 2021","July 28, 2020",,"July 31, 2020","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04489628"
30,"NCT04366791","Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","RESCUE 1-19","Recruiting","No Results Available","Pneumonia|Coronavirus Infection in 2019 (COVID-19)|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Radiation: Low Dose Radiation Therapy","Rate of extubation (for intubated patients)|Clinical outcome - Temperature|Clinical outcome - Heart Rate|Clinical outcome - Systolic blood pressure|Clinical outcome - Oxygenation|Clinical outcome - Respirations|Clinical outcome - FiO2|Clinical outcome - PEEP|Clinical outcome - Tidal volume|Clinical outcome - Intubation/Extubation events|Clinical outcome - Overall survival|Radiographic outcome - Chest xray|Radiographic outcome - CT can|Serologic outcome - WBC|Serologic outcome - Hgb|Serologic outcome - Procalcitonin|Serologic outcome - ANC|Serologic outcome - Creatine kinase|Serologic outcome - Myoglobin|Serologic outcome - Albumin|Serologic outcome - PT/PTT|Serologic outcome - D-Dimer|Serologic outcome - GGT|Serologic outcome -Triglycerides|Serologic outcome -Ferritin|Serologic outcome -Fibrinogen|Serologic Immune markers flow cytometry|Serologic outcome -Bilirubin|Serologic outcome - LDH|Serologic outcome - Creatinine|Serologic outcome - EGFR|Serologic outcome - CRP|Serologic outcome - ALT|Serologic outcome - AST|Serologic outcome - Troponin-I|Serologic outcome - BNP|Serologic outcome - Blood Gases pH|Serologic outcome - Blood Gases pO2|Serologic outcome - Blood Gases pCO2|Serologic outcome - Lactic Acid|Serologic outcome - IL-6|Serologic outcome - Potassium","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000476|NCI-2020-02676|RAD5002-20|P30CA138292","April 23, 2020","October 23, 2020","October 23, 2020","April 29, 2020",,"June 17, 2020","Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04366791/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04366791"
31,"NCT04397757","COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","843003 (PennCCP-02)","May 13, 2020","December 31, 2020","March 31, 2021","May 21, 2020",,"September 17, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04397757"
32,"NCT04470999","Changes in Cellular Immune Profile During COVID-19 Infection",,"Recruiting","No Results Available","Covid19|SARS-CoV-2","Other: Leukapheresis","Cellular immune system profiling|Innate immune system profiling|Expansion of virus-specific innate immune cells","Serhat Gumrukcu, MD PhD|The Scripps Research Institute|Seraph Research Institute","All","18 Years to 60 Years   (Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SRPH-CVD-01","April 15, 2020","September 30, 2020","December 31, 2020","July 14, 2020",,"July 20, 2020","Seraph Research Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04470999"
33,"NCT04442191","Convalescent Plasma as a Possible Treatment for COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma|Biological: Placebo","Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count","University of Illinois at Chicago","All","40 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0441","May 5, 2020","May 5, 2021","May 5, 2021","June 22, 2020",,"June 22, 2020","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04442191"
34,"NCT04338828","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","NO COV-ED","Recruiting","No Results Available","COVID19","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Massachusetts General Hospital|Department of Anesthesia, MGH","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019P00XXXX","April 18, 2020","April 2021","April 2022","April 8, 2020",,"May 20, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04338828"
35,"NCT04354870","COVID-19 PrEP HCW HCQ Study",,"Completed","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)","Frequency of seroconversion to SARS-CoV-2|Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion|Hospital admission rate|ICU admission rate|Mortality rate|Incidents of AEs or SAEs related to HCQ upon study termination time","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00390","April 3, 2020","September 15, 2020","October 1, 2020","April 21, 2020",,"October 5, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04354870"
36,"NCT04426344","Core Warming of COVID-19 Patients",,"Withdrawn","No Results Available","COVID 19","Device: ensoETM device","Viral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilation","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","202005150","October 2020","December 2020","December 2020","June 11, 2020",,"October 19, 2020","Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04426344"
37,"NCT04349371","Saved From COVID-19",,"Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Placebo oral tablet","Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9992","April 2020","April 2021","April 2021","April 16, 2020",,"April 21, 2020","Columbia University Irving Medical Center/NYP, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04349371"
38,"NCT04379492","A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19",,"Withdrawn","No Results Available","COVID-19|COVID19|Sars-CoV2|SARS-Cov-2","Drug: Hydroxychloroquine|Other: Placebo","Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI)|Number of participants requiring mechanical ventilation for respiratory failure","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-187","May 5, 2020","September 25, 2020","September 25, 2020","May 7, 2020",,"September 30, 2020","Memorial Sloan - Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04379492"
39,"NCT04570488","Predicting Favorable Outcomes in Hospitalized Covid-19 Patients",,"Recruiting","No Results Available","COVID|Corona Virus Infection|Adverse Event","Other: EPIC risk score display","Reduction in days from first low-risk score to discharge|Reduction in length of stay (LOS)|Reduction in GTD vs. LOS|No change in 30 day re-ED presentation or hospital admission rate for cohort","NYU Langone Health","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","PAU COVID19 RCT","May 15, 2020","December 30, 2020","May 15, 2021","September 30, 2020",,"October 14, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04570488"
40,"NCT04570462","Mild Hypothermia for COVID-19 ARDS",,"Recruiting","No Results Available","COVID19 ARDS","Other: Hypothermia Via Cooling Machine- Arctic Sun 5000","Changes in metabolic requirement during and after hypothermia|Changes in oxygen requirements and levels during and after hypothermia|length of intubation|Changes in carbon dioxide levels during and after hypothermia|does application of hypothermia reduce pro inflammatory response","Northwell Health","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol 5.18.2020 Approved","May 18, 2020","December 31, 2020","December 31, 2020","September 30, 2020",,"September 30, 2020","North Shore University Hospital, Manhasset, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04570462/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04570462"
41,"NCT04478019","SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding","SHIELD","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse","Number of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimen","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","94","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020","July 7, 2020","April 30, 2021","April 30, 2021","July 20, 2020",,"July 20, 2020","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04478019"
42,"NCT04512079","FREEDOM COVID-19 Anticoagulation Strategy","FREEDOM COVID","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Enoxaparin|Drug: Apixaban","Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism","Valentin Fuster|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","3600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 20-2115","September 8, 2020","March 2021","June 2021","August 13, 2020",,"October 14, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04512079"
43,"NCT04435808","Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection with SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine use on Need for Hospitalization with SARS-CoV-2 Infection|Impact of Hydroxychloroquine use on Need for ICU Care with SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","350","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-206","April 14, 2020","April 14, 2021","April 14, 2025","June 17, 2020",,"June 17, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04435808"
44,"NCT04365257","Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","PREVENT","Recruiting","No Results Available","COVID-19","Drug: Prazosin|Other: Standard of care","Death|Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO|Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)|Cumulative incidence of grade 3 and 4 adverse events|Number of participants with serious adverse events|Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin|Number of participants with laboratory abnormalities in peripheral blood|Duration of laboratory abnormalities in peripheral blood|Number of participants with laboratory abnormalities in plasma|Duration of laboratory abnormalities in plasma","Johns Hopkins University|Fast Grants","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246659|COV2001","May 13, 2020","December 2020","December 2020","April 28, 2020",,"May 15, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04365257"
45,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine and Azithromycin|Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"July 10, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
46,"NCT04462848","Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions",,"Not yet recruiting","No Results Available","Corona Virus Infection","Biological: anti-SARS-CoV-2 human convalescent plasma","Cumulative incidence of Grade 3 and Grade 4 adverse events|Cumulative incidence of serious adverse events|Proportion of participants with disease worsening event.|Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies|Percentage of participants with a natural antibody response to SARS-CoV-2 infection","University of California, Los Angeles","All","1 Month to 17 Years   (Child)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB#20-001263","August 2020","September 2024","December 2024","July 8, 2020",,"July 8, 2020","University of California, Los Angeles (UCLA), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04462848"
47,"NCT04371640","Sirolimus in COVID-19 Phase 1","SirCO-1","Recruiting","No Results Available","SARS-CoV-2|Covid-19","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse events","Walter K. Kraft|Thomas Jefferson University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15680","May 2020","July 2020","August 2020","May 1, 2020",,"May 7, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04371640"
48,"NCT04350450","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore",,"Withdrawn","No Results Available","COVID|Coronavirus|COVID-19","Drug: Hydroxychloroquine","Time to resolution of symptoms|Number of days from onset of illness to symptom resolution|Number of days to return to work|Rate of hospital admission in treated and untreated healthcare workers|Adverse effect of HCQ during treatment","Montefiore Medical Center","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-11445","April 2020","August 2020","August 2020","April 17, 2020",,"May 27, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04350450"
49,"NCT04524507","COVID-19 Antibody Plasma Research Study in Hospitalized Patients","UNC CCP RCT","Recruiting","No Results Available","COVID-19","Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2)","Cumulative Incidence of Serious Adverse Events (SAEs) at study Day 14|Days to hospital discharge (or discharge equivalent) following first dose of CCP","University of North Carolina, Chapel Hill","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-1544","August 27, 2020","May 2021","May 2021","August 24, 2020",,"October 5, 2020","University of North Carolina Health Care, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04524507"
50,"NCT04528771","S-Nitrosylation Therapy of COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV2 Infection|Covid19","Drug: SNO|Drug: Nitrogen gas","Length of Hospital Stay|Number of Ventilator Days|Length of Intensive Care|All-Cause Mortality|Treatment Emergent Adverse Events|Time to Respiratory Status Improvement|Clinical Status|Respiratory Clinical Status","Robert Schilz|Case Western Reserve University|University Hospitals Cleveland Medical Center","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY20200453","October 31, 2020","March 31, 2021","April 30, 2021","August 27, 2020",,"August 27, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04528771"
51,"NCT04372017","Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection",,"Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Cohort A: Percentage of COVID-19 exposed healthcare workers treated with hydroxychloroquine with a positive COVID-19 test.|Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with hydroxychloroquine with a positive COVID-19 test.","Sanford Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PEPCOH","May 14, 2020","June 4, 2020","June 4, 2021","May 1, 2020",,"June 9, 2020","Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04372017"
52,"NCT04485130","DISulfiram for COvid-19 (DISCO) Trial","DISCO","Not yet recruiting","No Results Available","Covid19","Drug: Disulfiram|Drug: Placebo","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)|Virologic impact of 3 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Immunologic impact of 3 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DSF151837","September 1, 2020","June 1, 2021","September 1, 2021","July 24, 2020",,"July 24, 2020","San Francisco General Hospital, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04485130"
53,"NCT04346628","Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19",,"Enrolling by invitation","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment","Time until cessation of oral shedding of SARS-CoV-2 virus|Sars-CoV-2 viral load|Count of participants with clinical worsening of COVID-19 disease|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Count of participant with absence of development of any symptoms|Cmax of favipiravir|Cmin of favipiravir","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56032","July 12, 2020","July 2021","July 2021","April 15, 2020",,"October 5, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04346628"
54,"NCT04433949","Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19","RESCUE1-19","Recruiting","No Results Available","Pneumonia|Severe Acute Respiratory Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed","Other: Best Practice|Radiation: Low Dose Radiation Therapy","Time to clinical recovery|Freedom from ICU admission|Temperature|Heart rate|Systolic Blood pressure|Oxygen saturation|Supplemental oxygenation need|Respiratory rate|Glasgow Comma Scale from minimum of 3 to maximum of 15.|Performance status|Survival|Serial chest x-rays severe acute respiratory syndrome (SARS) scoring|Changes on computed tomography (CT) scans pre and post RT|CRP|Serum chemistry + complete blood cell (CBC) with differential|Blood gases pH(when available)|Albumin|Procalcitonin|Aspartate aminotransferase (AST)|Creatine kinase|Prothrombin time (PT)/partial thromboplastin time (PTT)|Troponin|Lactate|NT-pBNP (cardiac injury)|Gamma-glutamyl transferase (GGT)|Triglycerides|Fibrinogen|Changes in CD8 T cells|Changes in CD4 T cells|Changes in serum antibodies against COVID-19 epitope|LDH|D-Dimer|IL-6|Myoglobin|Potassium|Ferritin|ALT","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 3","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000781|NCI-2020-04061|RAD5049-20|P30CA138292","June 12, 2020","May 30, 2022","May 30, 2022","June 16, 2020",,"June 16, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04433949"
55,"NCT04482621","Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","DART","Recruiting","No Results Available","COVID-19","Drug: Decitabine|Other: Placebo Saline","Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00247544","September 14, 2020","May 2021","July 2021","July 22, 2020",,"September 25, 2020","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04482621"
56,"NCT04412486","COVID-19 Convalescent Plasma (CCP) Transfusion",,"Recruiting","No Results Available","COVID-19","Biological: COVID Convalescent Plasma","Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.","Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0137","June 1, 2020","May 31, 2022","May 31, 2022","June 2, 2020",,"July 2, 2020","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT04412486"
57,"NCT04344535","Convalescent Plasma vs. Standard Plasma for COVID-19",,"Enrolling by invitation","No Results Available","COVID","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","28 day ventilator free days|90 day all-cause mortality","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBU-COVID19-ConvalescentPlasma","April 8, 2020","April 30, 2021","August 31, 2021","April 14, 2020",,"April 17, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344535"
58,"NCT04474483","Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Melatonin|Other: Placebo (Methylcellulose) capsule","Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality","State University of New York at Buffalo","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UBMELCOVID19","November 1, 2020","March 31, 2021","March 31, 2021","July 16, 2020",,"October 9, 2020","University at Buffalo, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04474483"
59,"NCT04343183","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection",,"Not yet recruiting","No Results Available","COVID-19","Device: Hyperbaric Oxygen Therapy","Decrease incidence of intubation by 30% or greater|Decrease renal injury","Ochsner Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00001051","April 2020","June 2020","June 2020","April 13, 2020",,"April 13, 2020","Ochsner Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04343183"
60,"NCT04456413","Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma|Other: Best Supportive Care","Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.","Hackensack Meridian Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","306","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020-0542","October 2020","July 2021","July 2021","July 2, 2020",,"September 23, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04456413"
61,"NCT04363346","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia",,"Recruiting","No Results Available","COVID-19","Drug: FT516","Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge","Masonic Cancer Center, University of Minnesota","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDIM-2020-28708|2020LS083","May 14, 2020","January 2022","January 2022","April 27, 2020",,"May 18, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04363346"
62,"NCT04345601","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)",,"Not yet recruiting","No Results Available","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","Biological: Mesenchymal Stromal Cells|Other: Supportive Care","Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-47561 MSC for COVID-19","August 2020","May 2022","May 2022","April 14, 2020",,"July 31, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04345601"
63,"NCT04530474","Outpatient Use of Ivermectin in COVID-19",,"Not yet recruiting","No Results Available","Covid19","Drug: Ivermectin Pill|Drug: Placebo","Clinical Improvement","Temple University","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","1285242","October 1, 2020","June 30, 2021","December 31, 2021","August 28, 2020",,"August 28, 2020","Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04530474"
64,"NCT04343755","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60","Hackensack Meridian Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2020-0375","April 9, 2020","April 2021","April 2021","April 13, 2020",,"July 16, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04343755"
65,"NCT04445285","Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure","DAMPENCOVID","Recruiting","No Results Available","Covid19","Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride","Mortality at 28 days|Systemic Therapeutic Response|Respiratory Response|Legnth of ICU Stay|Legnth of Hospital Stay|Pulmonary Function","Jon Simmons|University of South Alabama","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","USAH 1002 000","April 28, 2020","November 30, 2020","February 28, 2021","June 24, 2020",,"August 21, 2020","University of South Alabama, Mobile, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04445285"
66,"NCT04338074","TXA and Corona Virus 2019 (COVID19) in Outpatients","TCOutpatient","Recruiting","No Results Available","COVID-19","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Hospitalization","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID1","June 1, 2020","December 15, 2020","December 31, 2020","April 8, 2020",,"June 12, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338074"
67,"NCT04472611","Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial","COLSTAT","Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin","COVID 19 Severity","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000027950","August 1, 2020","August 1, 2021","August 1, 2022","July 15, 2020",,"July 31, 2020","Yale New Haven Hosptial System, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04472611"
68,"NCT04373161","Home Pulse Oximeter Use in Patients With COVID-19",,"Completed","No Results Available","Sars-CoV2|COVID-19|COVID","Device: Home Pulse Oximetry Monitoring","Hospitalization in COVID-19 patients with low home SpO2|Trend in resting home pulse oximetry readings|Timing of SpO2 <92%|Home pulse oximeter use effect on subsequent ED visits|Reason for return to the Emergency Department|Hospitalization outcome - morbidity|Hospitalization outcome - mortality|Median Length of Stay","Swedish Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","209","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020032301","March 20, 2020","April 22, 2020","April 22, 2020","May 4, 2020",,"May 6, 2020","Swedish Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04373161"
69,"NCT04409873","Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)","AMPoL","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Severe Acute Respiratory Syndrome Coronavirus 2|Virus Disease|Coronavirus Infections|Pharyngeal Diseases","Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water|Drug: Listerine Mouthwash Product","Change in SARS-Cov-2 viral load|Change in self-reported clinical symptom onset|Change in healthcare utilization and hospitalization","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","20-30874|R00RG2901","October 1, 2020","March 31, 2021","August 31, 2021","June 1, 2020",,"September 18, 2020","University Of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04409873"
70,"NCT04415151","Tofacitinib for Treatment of Moderate COVID-19","I-TOMIC","Recruiting","No Results Available","COVID-19","Drug: Tofacitinib 10 mg|Drug: Placebo","Disease Severity|Clinical improvement|Time to recovery|Time to clinical improvement|Clinical status|Mortality|Mechanical Ventilatory Support|Mechanical Ventilatory Support Duration|Freedom from mechanical ventilation|Adverse events|Additional intervention|Viral titer","Yale University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2000027848","July 29, 2020","March 31, 2021","March 31, 2021","June 4, 2020",,"October 8, 2020","Yale New Haven Health System, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04415151"
71,"NCT04388527","COVID-19 Convalescent Plasma for Mechanically Ventilated Population",,"Recruiting","No Results Available","Covid-19","Biological: COVID-19 Convalescent Plasma","Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842996 (PennCCP-01)","April 30, 2020","December 31, 2020","March 31, 2021","May 14, 2020",,"September 17, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04388527"
72,"NCT04542421","Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19",,"Recruiting","No Results Available","Covid19","Diagnostic Test: Lung ultrasound use in patients hospitalized with COVID","Adoption of lung ultrasound by hospitalists caring for patients with COVID|Percentage of patients with COVID who receive a lung ultrasound|Chest x-ray utilization|Adequacy of Lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert|Inpatient mortality","University of Colorado, Denver","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20-0781","July 1, 2020","July 1, 2021","December 1, 2021","September 9, 2020",,"September 28, 2020","University of Colorado, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04542421"
73,"NCT04374552","Asymptomatic COVID-19 Trial","ACT","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo","The primary outcome is the rate of decline in viral load over the 10 days after randomization","Rutgers, The State University of New Jersey","All","20 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro2020000872","May 5, 2020","November 2020","April 2021","May 5, 2020",,"May 5, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04374552"
74,"NCT04458363","Convalescent Plasma in Pediatric COVID-19",,"Recruiting","No Results Available","COVID","Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies","Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer","Emory University","All","up to 22 Years   (Child, Adult)","Early Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000789","July 2020","June 2022","June 2022","July 7, 2020",,"July 7, 2020","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04458363"
75,"NCT04363437","COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19","COMBATCOVID19","Recruiting","No Results Available","Coronavirus Infection","Drug: Colchicine|Drug: Usual Care","Percentage of Patients requiring supplemental oxygen beyond 8L nasal cannula|Percentage of patients who will require mechanical ventillation|Hospital length of stay|Mortality|Maximum CRP|Maximum troponin elevation","Maimonides Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-04-12","April 26, 2020","May 31, 2020","June 14, 2020","April 27, 2020",,"May 8, 2020","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04363437"
76,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
77,"NCT04519411","Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure",,"Recruiting","No Results Available","COVID 19","Diagnostic Test: Transpulmonary pressure measurements","Transpulmonary pressure","Mayo Clinic","All","up to 17 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-003743","May 21, 2020","December 31, 2020","January 31, 2021","August 19, 2020",,"August 19, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04519411"
78,"NCT04347538","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID 19","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200693","May 1, 2020","June 2021","June 2022","April 15, 2020",,"August 26, 2020","Vanderblt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04347538"
79,"NCT04435522","Maraviroc in Patients With Moderate and Severe COVID-19",,"Recruiting","No Results Available","COVID","Drug: Maraviroc","Rate of Completion|Clinical improvement at Day 7|Change in Chitinase 3-like 1(Chi3l1) (ng/mL)|Change in Interleukin-6 (IL-6) (pg/mL)|Change in CCL5 (RANTES) (ng/mL)|Mortality|Time to Discharge|Days on mechanical ventilation","Rhode Island Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1611471-1","September 21, 2020","December 31, 2020","January 2021","June 17, 2020",,"September 25, 2020","Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04435522"
80,"NCT04359329","Estrogen Patch for COVID-19 Symptoms",,"Recruiting","No Results Available","COVID","Drug: Estradiol patch","Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death","Sharon Nachman|Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBU-EstrogenPatch-COVID19","April 20, 2020","November 15, 2020","November 15, 2020","April 24, 2020",,"April 24, 2020","Stony Brook University Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359329"
81,"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","020-132","April 3, 2020","July 30, 2020","July 30, 2020","April 3, 2020",,"May 5, 2020","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04333225"
82,"NCT04406389","Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","IMPACT","Recruiting","No Results Available","COVID-19","Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban","30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Phase 4","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-04021936","October 13, 2020","December 2020","June 2021","May 28, 2020",,"October 20, 2020","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04406389"
83,"NCT04345653","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers",,"Active, not recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine Sulfate (HCQ)","Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation","Hackensack Meridian Health","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","44","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020-0356","April 14, 2020","June 5, 2020","April 8, 2021","April 14, 2020",,"June 9, 2020","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04345653"
84,"NCT04402970","Dornase Alfa for ARDS in Patients With SARS-CoV-2","DORNASESARS2","Recruiting","No Results Available","SARS-CoV 2|ARDS","Drug: Dornase Alfa Inhalation Solution","Improvement in PaO2/FiO2|Change in static lung compliance|Duration of mechanical ventilation|Length of ICU stay|Length of hospitalization|Secondary bacterial infections|Mortality","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2022206","June 19, 2020","May 31, 2021","May 31, 2022","May 27, 2020",,"June 26, 2020","University of Missouri Hospital and Clinics, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04402970"
85,"NCT04385901","Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth",,"Recruiting","No Results Available","SARS-CoV 2|SARS Pneumonia","Behavioral: Therapy Intervention","Change in 6 Minute Walk Test|Change in Short Form 35 (SF-36) Questionnaire|Change in Strength testing|Change in Peak Flow Meter Test","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID19Recovery","May 19, 2020","April 19, 2022","April 19, 2022","May 13, 2020",,"June 5, 2020","Missouri Orthopedic Institute, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04385901"
86,"NCT04479358","Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19","COVIDOSE-2","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Other: Standard of Care","Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor/Inotrope Utilization|Clinical Response: Duration of Vasopressor/Inotrope Utilization|Clinical Response: Time to Vasopressor/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","332","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-1179","September 10, 2020","December 1, 2020","March 1, 2021","July 21, 2020",,"September 23, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04479358"
87,"NCT04401423","TXA127 for the Treatment of Severe COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: TXA127|Drug: Placebo","Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAAT0535","August 2020","June 2021","December 2021","May 26, 2020",,"August 20, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04401423"
88,"NCT04506268","COVID-19 SAFE Enrollment","COVID SAFE","Enrolling by invitation","No Results Available","Covid19","Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email","Proportion Enrolled|Participant Age|Participant Sex|Participant Race/Ethnicity|Participant Income|Participant Education|Test Completion","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening","843565","September 9, 2020","October 9, 2020","November 2020","August 10, 2020",,"September 11, 2020","Penn Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04506268"
89,"NCT04340232","Safety and Efficacy of Baricitinib for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-0738","November 2020","August 2021","October 2021","April 9, 2020",,"August 25, 2020","University of Colorado, Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04340232"
90,"NCT04391712","Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease",,"Completed","No Results Available","COVID-19","Device: MLS Laser|Other: Regular Inpatient Medical Care","Patient Disposition Post treatment|oxygenation|IL-6 levels|Chest Xray radiographic results|Brescia-COVID Respiratory Severity Scale|SMART-COP Score|PSI Score|CRP levels","Lowell General Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020.01","April 30, 2020","May 15, 2020","July 16, 2020","May 18, 2020",,"August 5, 2020","Lowell General Hospital, Lowell, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04391712"
91,"NCT04353206","Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure",,"Recruiting","No Results Available","Covid-19|Sars-CoV2","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.","Noah Merin|Johns Hopkins University|Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Acute Care CP Consortium Trial","June 27, 2020","May 2021","May 2021","April 20, 2020",,"July 15, 2020","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04353206"
92,"NCT04459520","Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance",,"Completed","No Results Available","COVID-19","Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario","Behavioral Intentions|Personal Decisions Subscale|Social Expectations Subscale|Voting Behavior Question|Protest Question|Transportation","University of California, Los Angeles","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB#20-000980","July 23, 2020","July 28, 2020","July 29, 2020","July 7, 2020",,"August 20, 2020","UCLA Health Department of Medicine, Quality Office, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04459520"
93,"NCT04341935","Effects of DPP4 Inhibition on COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infection|Type 2 Diabetes","Drug: Linagliptin|Drug: Insulin regimen","Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures","University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200384","January 30, 2021","June 30, 2021","December 30, 2021","April 10, 2020",,"October 8, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04341935"
94,"NCT04389294","HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists",,"Recruiting","No Results Available","COVID","Diagnostic Test: SARS-CoV2 serum antibody testing","Correlation between serology testing and clinical suspicion of COVID-19|Prevalence of SARS-CoV2 exposure|Correlation of pre-existing risk factors with results of serology testing|Number of asymptomatic participants with positive antibody serology|Proportion of antibody- positive participants who subsequently develop COVID-19|Proportion of participants who are eligible for in plasma donation","Hospital for Special Surgery, New York","All","21 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2020-0850","May 5, 2020","September 30, 2020","October 30, 2020","May 15, 2020",,"May 15, 2020","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04389294"
95,"NCT04425720","Use of Remote Monitoring for COVID-19 Patient","RPM","Not yet recruiting","No Results Available","COVID","Device: LifeSignals Biosensor 1AX*|Other: Standard of Care","Monitored versus Non-Monitored in-patient admission|Emergency Department Visits|Length of stay|patient satisfaction|the incidence of mechanical ventilation and ECMO|serious adverse events","Montefiore Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2020-11824","August 31, 2020","June 1, 2021","June 1, 2021","June 11, 2020",,"August 31, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04425720"
96,"NCT04476953","COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation",,"Enrolling by invitation","No Results Available","COVID-19","Drug: Placebo|Drug: Fisetin","Serious Adverse Events|Change in oxygenation status|COVID-19 Severity Category","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-003936","August 3, 2020","July 2021","July 2021","July 20, 2020",,"August 13, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04476953"
97,"NCT04344015","COVID-19 Plasma Collection",,"Recruiting","No Results Available","COVID-19","Other: Plasma Donation","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20D.346","April 13, 2020","April 12, 2021","April 12, 2021","April 14, 2020",,"May 11, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04344015"
98,"NCT04570449","Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)",,"Not yet recruiting","No Results Available","Covid19","Drug: Fluoxetine|Drug: Placebo","Rate of hospitalization|Physical symptoms assessed through daily checklist|Rate of intubation|Rate of death|Depressive symptoms assessed weekly|Post traumatic stress disorder symptoms assessed weekly|Anxiety symptoms assessed weekly|Suicidality assessed daily","Milton S. Hershey Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00015598","September 2020","September 2021","October 2021","September 30, 2020",,"September 30, 2020","Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04570449"
99,"NCT04361838","The COVID-19 ICU PRAYER Study",,"Recruiting","No Results Available","Coronavirus Infection","Behavioral: prayer","Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.|Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.|Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score|Difference in patient outcomes - Length of stay in ICU.|Difference in patient outcomes - Length of ventilator support|Difference in patient outcomes - length of vasopressor support","Kansas City Heart Rhythm Institute","All","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Covid Prayer Study","June 1, 2020","August 31, 2020","August 31, 2020","April 24, 2020",,"June 4, 2020","Research Medical Center, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04361838"
100,"NCT04408040","Use of Convalescent Plasma for COVID-19",,"Recruiting","No Results Available","COVID","Biological: Convalescent Plasma","Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate","Northside Hospital, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","700","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 1281","July 14, 2020","July 31, 2022","July 31, 2022","May 29, 2020",,"July 28, 2020","Northside Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04408040"
101,"NCT04400890","Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Plant Polyphenol|Dietary Supplement: Vitamin D3","Hospitalization rates for COVID-19|ICU Admission Rates|Invasive Ventilation Rates","Marvin McCreary, MD|Mount Carmel Health System","All","45 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","McCreary2020","September 12, 2020","November 2020","January 2021","May 26, 2020",,"September 24, 2020","Mt Carmel HealthSystems, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04400890"
102,"NCT03376854","Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS","CHILL-pilot","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult|Sars-CoV2","Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care","Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days","University of Maryland, Baltimore","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00078506","May 1, 2018","November 30, 2020","December 31, 2020","December 19, 2017",,"June 16, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/ICF_011.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/SAP_012.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/Prot_013.pdf","https://ClinicalTrials.gov/show/NCT03376854"
103,"NCT04377308","Fluoxetine to Reduce Intubation and Death After COVID19 Infection",,"Recruiting","No Results Available","COVID-19|Cytokine Storm","Drug: Fluoxetine","Hospitalizations|Intubation|Death|Number of days of illness|PHQ-9 score for depressive symptoms,|generalized anxiety Disorder-7 scale","University of Toledo Health Science Campus","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FRIDA COVID19","May 1, 2020","April 20, 2021","October 20, 2021","May 6, 2020",,"May 6, 2020","University of Toledo, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04377308"
104,"NCT04502056","Covid-19 Messaging to Underserved Communities - 2nd Experiment",,"Not yet recruiting","No Results Available","Covid19","Behavioral: Acknowledgement Racial Injustice AMA|Behavioral: African American Sender Acknowledgement|Behavioral: African American Sender in Informational Videos.|Behavioral: Racial Inequality Highlighted|Behavioral: AMA Acknowledgement Drug Pricing|Behavioral: White Sender in Acknowledgement|Behavioral: White Sender in Informational Videos|Behavioral: No Racial Inequality Highlighting|Behavioral: Placebo videos","The number of participants with knowledge of COVID related symptoms and transmission as assessed by a questionnaire we've developed specifically relevant to the intervention videos we are using for the project.|Behavioral outcome 1: Number of participants who report behavior change related to messages provided in the intervention videos; measured via a specific questionnaire instrument we've developed to correspond to the intervention.|Behavioral outcome 2: Willingness to pay (WTP) for masks|Behavioral outcome 3: Number of people who click on links for additional information on the covid-19 behaviors|Behavioral outcome 4: The amount of money donated to a COVID-19 relief fund.","National Bureau of Economic Research, Inc.|Massachusetts General Hospital|Stanford University|Yale University|Harvard University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2029880","August 2020","September 2020","September 2021","August 6, 2020",,"August 6, 2020","JPAL North America, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04502056"
105,"NCT04494724","Clazakizumab vs. Placebo - COVID-19 Infection",,"Recruiting","No Results Available","COVID-19 Infection","Drug: Clazakizumab|Drug: Placebo","Primary Endpoint|Requirement for mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)|Infusion-related reactions during 24 hours from the time of infusion|Patient survival at 28 days|Patient survival at 60 days|Requirement for open-label clazakizumab|Time in the intensive care unit (ICU)|Time in the hospital|Time to mechanical ventilation|Clinical status improvement assessed by the World Health Organization (WHO) Clinical Progression Scale at day 14|Clinical status improvement assessed by World Health Organization (WHO) Clinical Progression Scale at day 28|Change in Radiologic Assessment of Lung Edema (RALE) at day 14|Change in Radiologic Assessment of Lung Edema (RALE) at day 28","The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00025969","July 13, 2020","December 31, 2020","July 31, 2021","July 31, 2020",,"July 31, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04494724"
106,"NCT04334512","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZDpaC","Recruiting","No Results Available","COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy","ProgenaBiome|DSCS CRO","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-044","June 22, 2020","June 2021","September 2021","April 6, 2020",,"July 20, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04334512"
107,"NCT04470544","Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","RECOVER","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Drug: Camostat Mesilate|Other: Standard of Care","Change in the proportion of patients alive and free from respiratory failure|Change in the proportion of patients alive and free of ventilator use or ECMO|Mortality Rate|Clinical Change|Adverse Events","Alan Bryce|Academic and Community Cancer Research United","All","18 Years and older   (Adult, Older Adult)","Phase 2","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAM20CV","July 28, 2020","September 15, 2022","September 15, 2022","July 14, 2020",,"September 25, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04470544"
108,"NCT04427566","Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise","VENTED","Recruiting","No Results Available","COVID-19","Radiation: Radiation therapy","Mortality rate of subjects treated with whole lung low-dose radiation|Survival rate of subjects treated with whole lung low-dose radiation|Change in number of Intensive care unit days|Change in number of days using supplemental oxygen|Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated|Quantitation of Lung Involvement using Chest CT|Quantitation of Lung Opacities using Chest CT|SARS-CoV2 viral titers|Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs|Change in performance status after low dose radiation to lungs","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VENTED","July 23, 2020","December 31, 2021","December 31, 2021","June 11, 2020",,"September 25, 2020","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04427566"
109,"NCT04456153","Atovaquone for Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Experimental Group|Drug: Placebo Group","Viral Load","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STU-2020-0707","July 22, 2020","December 2020","March 2021","July 2, 2020",,"July 30, 2020","University of Texas Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04456153"
110,"NCT04559035","Nasal Irrigation to Reduce COVID-19 Morbidity",,"Enrolling by invitation","No Results Available","Covid19","Other: Nasal lavage","Frequency|Reduction","Augusta University","All","55 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1603291","September 24, 2020","December 31, 2020","December 31, 2020","September 22, 2020",,"September 22, 2020","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04559035"
111,"NCT04334967","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care",,"Suspended","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 4","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020000186","March 30, 2020","May 27, 2021","May 27, 2022","April 6, 2020",,"September 16, 2020","Portland Providence Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04334967"
112,"NCT04365985","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","SINK COVID-19","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections","Drug: Naltrexone|Drug: Ketamine|Other: Placebo","Progression of oxygenation needs|Renal failure|Liver failure|Cytokine Storm|Mortality|Length of hospital stay|Intensive Care Unit (ICU) admission|Intensive Care Unit (ICU) duration|Intubation|Intubation duration|Time until recovery","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020-097","April 29, 2020","May 2021","August 2021","April 28, 2020",,"July 2, 2020","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04365985"
113,"NCT04359797","COVID-19 Patient Positioning Pragmatic Trial",,"Enrolling by invitation","No Results Available","COVID-19","Other: Prone|Other: Usual Care","Modified WHO Ordinal Scale|FIO2","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","200727","April 27, 2020","April 2021","June 2021","April 24, 2020",,"October 8, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04359797"
114,"NCT04361214","Leflunomide in Mild COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Leflunomide","Tolerability of high dose leflunomide as measured by leflunomide dose modifications|Tolerability of high dose leflunomide as measured by discontinuation of leflunomide|Tolerability of high dose leflunomide as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0622","May 5, 2020","September 2020","September 2020","April 24, 2020",,"August 25, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04361214"
115,"NCT04343690","COPING With COVID-19( CWC-19)",,"Withdrawn","No Results Available","COVID-19","Behavioral: Crisis management coaching","Change in stress level as measured by survey|Change wellness as measured by survey","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00105319","March 27, 2020","May 1, 2020","May 1, 2020","April 13, 2020",,"September 23, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04343690"
116,"NCT04568122","Rapid Turnaround, Home-based Saliva Testing for COVID-19",,"Not yet recruiting","No Results Available","Covid19","Device: Saliva test kit","An indicator for discrepancy in interpretation of findings by participant versus by technician via photo (interrater reliability)|An indicator for whether the home saliva test is positive as determined by the patient (to assess sensitivity and specificity by the patient)|An indicator for ambiguous findings as measured by percent confidence (if < 80% confident) in interpretation of results by participant and by technician (ease of interpretation)|An indicator that the participant appropriately followed instructions for using the kit (≥ 80% confident) (ease of use)|An indicator for whether participant called technical support and by reason (e.g., centrifuging was not possible due to broken part) (ease of use)|An indicator by participant that the sample was sufficient and reached the indicated line for sample integrity (sample integrity)|An indicator for whether the home saliva test is positive as determined by the technician (to assess sensitivity and specificity by the technician)","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3015","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","58629","October 2020","January 2021","April 2021","September 29, 2020",,"October 12, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04568122"
117,"NCT04361253","Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy","(ESCAPE)","Recruiting","No Results Available","COVID|Infectious Disease","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)","Modified WHO Ordinal Scale (MOS) score","Brigham and Women's Hospital","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001215","April 30, 2020","June 2021","December 2021","April 24, 2020",,"May 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04361253"
118,"NCT04332081","Hyperbaric Oxygen for COVID-19 Patients",,"Terminated","No Results Available","COVID-19","Device: hyperbaric oxygen therapy (HBOT)","Mortality|Need for mechanical ventilation|Days on invasive mechanical ventilation","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00399","April 6, 2020","May 29, 2020","May 29, 2020","April 2, 2020",,"June 4, 2020","NYU Winthrop Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT04332081"
119,"NCT04389710","Convalescent Plasma for the Treatment of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20D.379","April 15, 2020","April 14, 2021","April 14, 2021","May 15, 2020",,"June 25, 2020","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04389710"
120,"NCT04365699","Cardiovascular Effects of COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: AT-001","Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization|Incidence of Adverse Events for patients receiving AT-001|Change in left ventricular ejection fraction|Change in left ventricular end-diastolic diameter|Change in left ventricular end-systolic diameter|Change in biomarkers of cardiac injury|Frequency of atrial fibrillation|Frequency of heart block|Frequency of non-sustained ventricular tachycardia|Frequency of sustained ventricular tachycardia|Frequency of ventricular fibrillation|Proportion of subjects requiring mechanical ventilation|Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-00416","April 8, 2020","December 31, 2020","December 31, 2020","April 28, 2020",,"April 28, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04365699"
121,"NCT04353284","Camostat Mesylate in COVID-19 Outpatients",,"Recruiting","No Results Available","COVID-19","Drug: Camostat Mesilate|Other: Placebo","Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027971","June 19, 2020","May 31, 2021","May 31, 2021","April 20, 2020",,"September 7, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04353284"
122,"NCT04487444","Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection","Ta1","Recruiting","No Results Available","Covid19","Drug: Thymalfasin","Time to recovery (free of respiratory failure)|Lymphopenia|Survival|Hospital length of stay|Requirement for high flow oxygen supplementation|Duration of high flow oxygen supplementation|ICU admission|ICU length of stay|Mechanical ventilation|Duration of mechanical ventilation|Change in any existing comorbidities (e.g., worsening congestive heart failure) or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections (other respiratory, urinary tract, cellulitis, etc.)|AEs/SAEs|Changes to vital signs|Changes in laboratory parameters","Rhode Island Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCN-16130571-2","September 10, 2020","March 2021","June 2021","July 27, 2020",,"September 14, 2020","The Miriam Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04487444"
123,"NCT04359277","A Randomized Trial of Anticoagulation Strategies in COVID-19",,"Terminated","No Results Available","COVID-19","Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation","Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock|Score on WHO Ordinal Scale|Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))|Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Cardiac injury|Hypercoagulability|Disseminated Intravascular Coagulation (DIC) Score|Length of Hospital Stay","NYU Langone Health","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00479","April 21, 2020","September 20, 2020","September 20, 2020","April 24, 2020",,"October 8, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04359277"
124,"NCT04356690","Etoposide in Patients With COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Etoposide","Change in pulmonary status|Change in ferritin levels|Change in C-reactive protein levels|Change in d-dimer levels|Change in white blood cell count|Incidence of serious adverse events|Overall survival|Length of hospitalization|Duration of ventilation|Ventilator free days|Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)","Boston Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40102","May 8, 2020","December 2020","December 2021","April 22, 2020",,"September 4, 2020","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356690"
125,"NCT04412785","Cyclosporine in Patients With Moderate COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Cyclosporine","Safety-oxygen, ICU transfer and ventilation|Safety-changes in absolute lymphocyte count|Safety-changes in creatinine clearance|Safety-secondary bacterial infections|Laboratory measurements of safety and antiviral efficacy related to COVID-19-SARS-CoV-2 by measuring the clearance of SARS-CoV-2 from respiratory secretions|Laboratory measurements-D-dimer levels|Laboratory measurements-ferritin|Laboratory measurements- IL-6","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","842998","June 22, 2020","September 2020","December 2020","June 2, 2020",,"June 29, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04412785"
126,"NCT04570501","Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients",,"Not yet recruiting","No Results Available","Covid19","Drug: Angiotensin-(1-7)|Drug: Placebo","Time to recovery|Incidence of mortality at Day 29|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","58189","November 2020","May 2021","May 2021","September 30, 2020",,"September 30, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04570501"
127,"NCT04394416","Trial of Imatinib for Hospitalized Adults With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Imatinib|Drug: Placebo oral tablet","The proportion of patients with a two-point change using the 8-category ordinal scale|All-Cause mortality|Time to a 2-point clinical change|Hospitalization|Duration of ECMO or invasive mechanical ventilation|Duration of ICU stay|SARS-CoV-2 negative|Negative oropharyngeal or nasopharyngeal swab|Serious adverse events (SAEs)|Discontinuation due to adverse events","University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Phase 3","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2038GCCC","June 2, 2020","June 1, 2022","June 1, 2023","May 19, 2020",,"June 4, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04394416"
128,"NCT04374461","A Study of N-acetylcysteine in Patients With COVID-19 Infection",,"Recruiting","No Results Available","Covid-19","Drug: N-acetylcysteine|Other: Peripheral Blood","Arm A: number of patients who are successfully extubated and/or transferred out of critical care due to clinical improvement|Arm B: number of patients who are discharged from the hospital due to clinical improvement","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-168","May 1, 2020","May 2021","May 2021","May 5, 2020",,"October 5, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04374461"
129,"NCT04514627","Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19","PENFS COVID-19","Recruiting","No Results Available","COVID-19","Device: Auricular percutaneous neurostimulation","Hypoxemia via oxygen level, or saturation (SpO2) in percent|Progression to mechanical ventilation, ECLS or death|Oxygen requirements|Days of hospitalization|Time to hospital discharge|Time to resolution of fever|Days of resting respiratory rate|Serious adverse events or patient or worsening condition|Erythrocyte Sedimentation Rate (ESR)|C-Reactive Protein (CRP)|Ferritin|D-Dimer|Creatine Phosphokinase, Total (CK)|Troponin|Lactate Dehydrogenase (LDH)|Procalcitonin (PCT)|B-Type Natriuretic Peptide (BNP)|N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP)|Interleukin-6 (IL-6), High Sensitive ELISA|Complete Blood Count (CBC) with Differential|Comprehensive Metabolic Panel (CMP)|7-Point Ordinal Scale of Clinical Status|Modified Borg Dyspnea Scale (MBS)","Olive View-UCLA Education & Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1600899","July 13, 2020","July 31, 2021","July 31, 2021","August 17, 2020",,"August 19, 2020","Olive View-UCLA Medical Center, Sylmar, California, United States",,"https://ClinicalTrials.gov/show/NCT04514627"
130,"NCT04329923","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Ravi Amaravadi, MD|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","842838","April 9, 2020","April 1, 2021","December 1, 2021","April 1, 2020",,"April 28, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04329923"
131,"NCT04372004","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","CATCH COVID-19","Recruiting","No Results Available","COVID-19","Diagnostic Test: diagnostic tests for COVID-19 infection","detection of viral infection using serology and viral-RNA detection kits|Temporal trend of antibodies in blood","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TCAI_CATCH COVID-19","May 8, 2020","May 2021","June 2021","May 1, 2020",,"August 11, 2020","Texas Cardiac Arrhythmia Institute, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04372004"
132,"NCT04524663","Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","COPS-2002","Not yet recruiting","No Results Available","Covid19","Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment","Time until cessation of shedding of SARS-CoV-2 virus|Clinical worsening of COVID-19 disease in symptomatic patients|Development of antibodies to SARS-CoV-2|Time until resolution of symptoms|Time until progression of symptoms|Drug level on day five, one hour after a dose taken on an empty stomach","Stanford University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56029","October 2020","April 2021","April 2021","August 24, 2020",,"October 20, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04524663"
133,"NCT04490824","Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals",,"Recruiting","No Results Available","Covid19","Device: KELEA Excellerated Water|Device: Water Without an Elevated Level of KELEA","Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals","Institute of Progressive Medicine","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KELEA-1","October 1, 2020","October 31, 2020","November 30, 2020","July 29, 2020",,"September 18, 2020","Institute of Progressive Medicine, South Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT04490824"
134,"NCT04412772","A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS","ARCHITECTS","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Placebo","Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RA-2020-019","June 1, 2020","December 31, 2021","December 31, 2021","June 2, 2020",,"June 2, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04412772"
135,"NCT04351620","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Tolerability of high dose HCQ as measured by HCQ dose modification|Tolerability of high dose HCQ as measured by discontinuation of HCQ|Tolerability of High Dose HCQ as measured by Adverse Events|Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized|Time to defervescence as measured in days while on treatment protocol|Resolution of other COVID-19 symptoms measured in days while on treatment protocol","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0572","April 2020","June 2020","June 2020","April 17, 2020",,"April 17, 2020","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04351620"
136,"NCT04490486","Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19","COVID-19","Not yet recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Corona Virus Infection","Biological: UCMSCs|Other: Placebo","Percent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms","Joshua M Hare|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200575","March 1, 2021","June 1, 2024","June 1, 2024","July 29, 2020",,"September 9, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04490486"
137,"NCT04438057","Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: CCP","Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days","Metro Infectious Disease Consultants","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIDC-CCP","August 12, 2020","August 12, 2020","August 12, 2021","June 18, 2020",,"August 21, 2020","Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04438057"
138,"NCT04339426","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection",,"Recruiting","No Results Available","Covid19","Drug: Atovaquone/Azithromycin","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","HonorHealth Research Institute","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HRI-COVID-19-Anti-Malarial-001","April 20, 2020","October 2020","April 2021","April 9, 2020",,"June 9, 2020","HonorHealth, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04339426"
139,"NCT04393311","Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ulinastatin|Drug: Placebo","Time to recovery|COVID-19 disease severity scale score on Day 8|COVID-19 disease severity scale score on Day 15|COVID-19 disease severity scale score on Day 22|COVID-19 disease severity scale score on Day 29|Incidence of mortality at Day 29|Incidence of in-hospital mortality|Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose|Number of patients with resolution of symptoms defined as score of 8 on the 8-point ordinal scale at Day 29|Number of patients alive and free of respiratory failure defined as score of 4, 5, 6, 7, or 8 on the 8-point ordinal scale at Day 29|Duration of mechanical ventilation|Duration of ECMO|Duration of noninvasive ventilation|Duration of ICU stay|Duration of hospital stay|Change in oxygen saturation","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","56639","November 2020","May 2021","May 2021","May 19, 2020",,"September 30, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04393311"
140,"NCT04429867","Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo","Impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.|Hospital length of stay|30-Day Mortality|Resolution of Symptoms|Incidence of QTc >500ms after initiation of therapy|Incidence of discontinuation of therapy","WellStar Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1604885","May 7, 2020","December 7, 2020","December 7, 2020","June 12, 2020",,"June 16, 2020","Wellstar Kennestone Hospital, Marietta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04429867"
141,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Completed","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 4, 2020","June 5, 2020","June 5, 2020","April 2, 2020",,"August 3, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
142,"NCT04377659","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Progression of respiratory failure or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-185","May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",,"August 21, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04377659"
143,"NCT04344444","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","RCT","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Most severe outcome","LCMC Health","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID 2020-001","April 13, 2020","April 10, 2021","December 10, 2021","April 14, 2020",,"August 24, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344444"
144,"NCT04363502","Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","Covid19","Drug: Clazakizumab|Drug: Placebo","Change in C-reactive protein (CRP) level","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00247932","May 7, 2020","December 2020","December 2020","April 27, 2020",,"August 19, 2020","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04363502"
145,"NCT04344236","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient","NYU Langone Health","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00444","April 9, 2020","May 1, 2020","May 9, 2020","April 14, 2020",,"April 14, 2020","NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04344236"
146,"NCT04345692","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","OAHU-COVID19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RA-2020-018","March 26, 2020","December 31, 2021","December 31, 2021","April 14, 2020",,"June 4, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04345692"
147,"NCT04434131","Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Convalescent Plasma","Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-227","April 28, 2020","April 28, 2021","April 28, 2025","June 16, 2020",,"June 16, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04434131"
148,"NCT04331899","Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","COVID-Lambda","Active, not recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Placebo","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR|Sars-CoV-2 viral load|Area under the curve of SARS-COV-2 viral load|Time to alleviation of all symptoms Time to alleviation of all symptoms|Number of participants requiring emergency department visits or hospitalizations within 28 days of initiation of treatment","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","55619","April 24, 2020","August 14, 2020","May 2021","April 2, 2020",,"September 28, 2020","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04331899"
149,"NCT04370782","Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline","Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms","St. Francis Hospital, New York","All","30 Years and older   (Adult, Older Adult)","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-21","April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",,"May 18, 2020","St Francis Hospital, Roslyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370782"
150,"NCT04381923","COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia","COVIDNOCHE","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Hypoxemic Respiratory Failure|Pneumonia, Viral|COVID","Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO)","Ventilator-Free Days (VFD)|ICU and Hospital Length of Stay|Intubation|Renal Replacement Therapy (RRT)|Mortality","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","843124","August 15, 2020","February 15, 2021","May 15, 2021","May 11, 2020",,"July 28, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04381923"
151,"NCT04360551","Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Telmisartan 40mg|Drug: Placebo","Maximum clinical severity of disease|Incidence of treatment emergent adverse events|Renin angiotensin system peptides|Plasma biomarkers","University of Hawaii","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H051","July 1, 2020","June 30, 2021","June 30, 2021","April 24, 2020",,"August 3, 2020","University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04360551"
152,"NCT04343989","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo","Cumulative incidence of serious adverse events associated with clazakizumab or placebo|Cumulative incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient Survival","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","s20-00392","March 31, 2020","July 1, 2020","July 1, 2020","April 14, 2020",,"May 6, 2020","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04343989"
153,"NCT04481685","A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",,"Recruiting","No Results Available","Covid19","Drug: ATI-450|Drug: Placebo","Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor (TNF-α)","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IIT-2020-ATI-450-COVID-19","July 20, 2020","July 2021","July 2022","July 22, 2020",,"August 21, 2020","The University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04481685"
154,"NCT04374149","Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS",,"Active, not recruiting","No Results Available","Cytokine Release Syndrome|COVID19","Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib","Overall Response Rate","Prisma Health-Upstate","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHU COVID-19-001","April 30, 2020","September 25, 2020","December 1, 2020","May 5, 2020",,"September 16, 2020","Prisma Health, Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04374149"
155,"NCT04349410","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","FMTVDM","Completed","No Results Available","CoVid 19 Positive","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","The Camelot Foundation","All","Child, Adult, Older Adult","Phase 2|Phase 3","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","FMTVDM2020","April 11, 2020","September 14, 2020","September 14, 2020","April 16, 2020",,"October 8, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04349410"
156,"NCT04368000","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","PAPR","Active, not recruiting","No Results Available","Respiratory Failure|COVID-19","Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions","Change in imputed partial pressure of oxygen over fraction of inspired oxygen (PaO2/FiO2) from peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2)|Change in imputed PaO2/FiO2 from SpO2/FiO2|Proportion of participants requiring endotracheal intubation|Proportion of participants requiring mechanical ventilation|Proportion of participants transferred to intensive care for worsening respiratory failure|Proportion of participants who had escalated oxygen delivery needs|Average number of days hospitalized|Average number of ventilator-free days|Proportion of participants discharged from hospital on hospice|Proportion of participants with all-cause inpatient mortality","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00132123","April 29, 2020","December 2020","January 2021","April 29, 2020",,"August 26, 2020","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04368000"
157,"NCT04392323","Incidence of COVID-19 Test Conversion in Post-surgical Patients",,"Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 PCR and Serology","COVID-19 Test Conversion|Duration of Hospitalization|Rate of self-reported COVID-19 exposure|Rate of complications from COVID-19","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB #20-0404","May 13, 2020","July 1, 2020","July 31, 2020","May 18, 2020",,"May 18, 2020","North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT04392323"
158,"NCT04342663","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","STOP COVID","Active, not recruiting","No Results Available","COVID 19|Coronavirus","Drug: Fluvoxamine|Drug: Placebo","Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","202004023","April 10, 2020","August 20, 2020","October 1, 2020","April 13, 2020",,"September 1, 2020","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04342663"
159,"NCT04342728","Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","COVIDAtoZ","Enrolling by invitation","No Results Available","COVID|Corona Virus Infection","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Symptom Resolution: Muscle/body aches|Symptom Resolution: Headache|Symptom Resolution: New loss of taste|Symptom Resolution: New loss of smell|Symptom Resolution: Congestion/ runny nose|Symptom Resolution: Nausea|Symptom Resolution: Vomiting|Symptom Resolution: Diarrhea|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB 20-361","April 8, 2020","December 30, 2020","April 30, 2021","April 13, 2020",,"August 14, 2020","Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04342728"
160,"NCT04589117","Expressive Writing for COVID-19 Resilience for Parents",,"Completed","No Results Available","Parents During COVID-19","Behavioral: Expressive writing","Resilience|Perceived stress|Depression symptoms|Parental stress","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00105586","May 27, 2020","August 2, 2020","August 2, 2020","October 19, 2020",,"October 19, 2020","Duke Integrative Medicine, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04589117"
161,"NCT04341727","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU352","Suspended","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Hours to recovery|Time fever resolution","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202003188","April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",,"June 4, 2020","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04341727"
162,"NCT04589104","Expressive Writing for COVID-19 Resilience",,"Completed","No Results Available","Distress Due to COVID-19","Behavioral: Expressive writing","Resilience|Perceived stress|Depression symptoms|Post-traumatic growth","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","63","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00105575","May 26, 2020","August 17, 2020","August 17, 2020","October 19, 2020",,"October 19, 2020","Duke Integrative Medicine, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04589104"
163,"NCT04478071","Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|Coronavirus Infection","Drug: vadadustat|Drug: placebo","Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale|Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale","The University of Texas Health Science Center, Houston|Akebia Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-20-0395","August 22, 2020","August 1, 2022","August 1, 2022","July 20, 2020",,"September 10, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04478071"
164,"NCT04374565","Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia",,"Active, not recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200114","May 5, 2020","April 5, 2021","April 5, 2021","May 5, 2020",,"August 21, 2020","University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04374565"
165,"NCT04476940","COVID-19 Breastfeeding Guideline for African-Americans","COVID-BF","Not yet recruiting","No Results Available","Covid19|Exclusive Breastfeeding","Behavioral: COVID-19 Breastfeeding Support","COVID-19 breastfeeding guidance adherence at birth.|COVID-19 breastfeeding guidance adherence at 1-month postpartum.|COVID-19 breastfeeding guidance adherence at 3-months postpartum.|Exclusive breastfeeding at birth.|Exclusive breastfeeding at 1-month.|Exclusive breastfeeding at 3-months.|COVID_Status|COVID-19 Immunoglobulin G|COVID-19 Immunoglobulin M","Meharry Medical College","Female","18 Years to 45 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","330875","September 2020","October 2021","June 2022","July 20, 2020",,"July 20, 2020","Meharry Medical College, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04476940"
166,"NCT04407286","Vitamin D Testing and Treatment for COVID 19",,"Recruiting","No Results Available","Covid 19|Vitamin D Deficiency","Dietary Supplement: Vitamin D3","Vitamin D levels|severity of COVID 19 symptoms","Arizona State University|Southwest College of Naturopathic Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00011960","May 19, 2020","October 18, 2020","May 18, 2021","May 29, 2020",,"September 2, 2020","Arizona State University, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04407286"
167,"NCT04355897","CoVID-19 Plasma in Treatment of COVID-19 Patients",,"Recruiting","No Results Available","COVID 19","Biological: Convalescent COVID 19 Plasma","Reduce mortality|Reduce requirement for mechanical ventilation.|Reduce the duration of mechanical ventilation.|Review of treatment related adverse events.","The Christ Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-23","April 28, 2020","July 2020","August 2020","April 21, 2020",,"May 20, 2020","The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04355897"
168,"NCT04495816","COVID-19 Anosmia Study",,"Recruiting","No Results Available","Anosmia|Covid19","Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control","Brief Smell Identification Test (BSIT)|Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)|Sinonasal Outcomes Test (SNOT-22)","Icahn School of Medicine at Mount Sinai","Female","18 Years and older   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 20-1132","July 15, 2020","April 2021","June 2021","August 3, 2020",,"August 4, 2020","Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04495816"
169,"NCT04480411","Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients",,"Not yet recruiting","No Results Available","Diagnoses Disease|Covid19","Behavioral: Use of Doctorgram Patient Kit|Behavioral: Use of Doctorgram Mobile Application|Behavioral: Use of Remote Pulse Oximeter","Hospital admission rate|Hospital re-admission rate|Hospital length of stay|Patient provider experience survey score|Provider experience survey score|Use of personal protective improvement|Number of in-patient encounters with COVID patients as a measure of provider exposure to high risk illness","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","165","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","56472","October 2020","February 2021","February 2021","July 21, 2020",,"September 9, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04480411"
170,"NCT04355728","Use of UC-MSCs for COVID-19 Patients",,"Active, not recruiting","No Results Available","Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19","Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care","Incidence of pre-specified infusion associated adverse events|Incidence of Severe Adverse Events|Survival rate after 90 days post first infusion|Ventilator-Free Days|Change in Oxygenation Index (OI)|Plat-PEEP|Sequential Organ Failure Assessment (SOFA) Scores|Small Identification Test (SIT) scores|Troponin I levels|C-Reactive Protein levels|Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio|D-dimer levels|25-Hydroxy Vitamin D levels|Alloantibodies levels|Blood white cell count|Platelets count","Camillo Ricordi|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20200671","April 25, 2020","October 25, 2020","December 31, 2020","April 21, 2020",,"August 14, 2020","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04355728"
171,"NCT04402840","Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Procedure: Stellate Ganglion Block","Adverse events related to SGB|All Adverse events|Death|PaO2/FiO2 or SpO2/FiO2(SF) ratio change from baseline|Radiographic criteria|Incidence of cardiac arrhythmia|Resolution of cardiac arrhythmia|Cardiac function|Clinical relevant Laboratory testing (d-dimer, Ferritin, Troponin T, LDH)","West Virginia University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004963113","April 24, 2020","July 2020","December 2020","May 27, 2020",,"May 27, 2020","West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04402840"
172,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","March 30, 2020","December 18, 2020","December 31, 2021","April 1, 2020",,"September 2, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
173,"NCT04342689","The Role of Resistant Starch in COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score","Yale University|University of Michigan|University of Minnesota","All","19 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2000027887","June 3, 2020","June 1, 2021","June 1, 2021","April 13, 2020",,"June 17, 2020","Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04342689"
174,"NCT04391179","Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","DICER","Recruiting","No Results Available","COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection","Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet","Change in D-dimer|Global composite rank score","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HUM00179783","May 31, 2020","December 2020","December 2020","May 18, 2020",,"July 31, 2020","North Shore UniversityHealth, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04391179"
175,"NCT04360824","Covid-19 Associated Coagulopathy",,"Recruiting","No Results Available","COVID 19 Associated Coagulopathy","Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis","Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions","University of Iowa","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202004235","May 6, 2020","April 16, 2021","April 16, 2021","April 24, 2020",,"June 19, 2020","University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04360824"
176,"NCT04424901","Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19","TOLD","Recruiting","No Results Available","COVID-19 Pneumonia|Vascular Complications","Drug: Dipyridamole","Coagulation system|Viral Detection","UConn Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-192-2.F","May 3, 2020","May 1, 2021","May 30, 2021","June 11, 2020",,"June 11, 2020","UConn Health, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04424901"
177,"NCT04558125","Low-Dose Tenecteplase in Covid-19",,"Active, not recruiting","No Results Available","Pulmonary Embolism|COVID","Drug: TNKase","Percent improvement in shock index (HR/SBP) 6 hours after the TNK/placebo bolus.|1. Clinical status at 24 hours after administration of TNK / placebo based upon 7-point scale.","Cedars-Sinai Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ML42522","September 8, 2020","December 31, 2021","June 30, 2022","September 22, 2020",,"September 22, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04558125"
178,"NCT04344457","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","Perseverance Research Center, LLC|Athena Medical Group","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIZ-PRC-COVID-19","April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",,"July 1, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344457"
179,"NCT04460703","COVID-19 Vaccine Messaging, Part 1",,"Completed","No Results Available","Vaccination|COVID-19","Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message","Intention to get COVID-19 vaccine|Vaccine confidence scale|Persuade others item|Fear of those who have not been vaccinated|Social judgment of those who do not vaccinate","Yale University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000027983","July 3, 2020","July 8, 2020","July 8, 2020","July 7, 2020",,"July 21, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04460703"
180,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
181,"NCT04342169","University of Utah COVID-19 Hydrochloroquine Trial",,"Recruiting","No Results Available","Coronavirus Infection|Coronavirus|Infectious Disease","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00131893","April 4, 2020","April 2022","April 2023","April 10, 2020",,"August 20, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04342169"
182,"NCT04312243","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","Recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Massachusetts General Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NOpreCOVID-19","April 7, 2020","April 7, 2021","April 7, 2022","March 18, 2020",,"June 16, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04312243"
183,"NCT04547283","Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19",,"Recruiting","No Results Available","Covid19|Respiratory Failure","Other: Usual Care|Other: APPS","Average S/F ratio|Time spent with S/F ratio < 315|Highest oxygen support|Number of patients requiring ICU admission during study period|Number of patients requiring ICU admission during hospitalization|Number of patients experiencing who die prior to discharge|Number of patients requiring intubation|Hospital length of stay","Atrium Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","06-20-03E","June 14, 2020","September 20, 2020","September 30, 2020","September 14, 2020",,"September 14, 2020","Carolinas Medical Center, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04547283"
184,"NCT04362111","Early Treatment of Cytokine Storm Syndrome in Covid-19",,"Recruiting","No Results Available","Cytokine Storm|COVID-19","Drug: Anakinra|Drug: Normal saline","Percentage of patients discharged from the hospital alive and without the need for mechanical ventilation.|Percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours|Percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery/respiratory support measures after 48 hours.|Average time in days to achieve sustained ≥93% oxygen saturation without oxygen/respiratory support|Percentage of subjects with resolution of laboratory markers of Cytokine Storm syndrome|Percentage of subjects who develop bacterial or fungal or non-Covid-19 viral infection|Percentage of subjects who develop neutralizing antibody to Covid-19","University of Alabama at Birmingham","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Chatham-Cytokine Covid-19","July 29, 2020","January 2021","March 2021","April 24, 2020",,"September 11, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04362111"
185,"NCT04369742","Treating COVID-19 With Hydroxychloroquine (TEACH)",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate","Cumulative incidence of SAEs through day 30|Cumulative incidence of grade 3 or 4 AEs through day 30|Incidence of discontinuation of therapy (for any reason)|Severe disease progression composite outcome|Cumulative incidence of events|Hospital length of stay|Days of fever|Days of non-invasive ventilator use|Days of non-rebreather mask oxygen supplementation|Score on Cytokine Release Syndrome (CRS) Grading Scale|Percentage of subjects reporting each severity score on 8 point ordinal scale Day 1 and EOT (End of Treatment - Day 6)|Percentage of subjects with qTC prolongation at EOT|Cumulative Incidence of mortality|Cumulative Incidence of ICU admission|Cumulative Incidence of Invasive mechanical ventilation|Cumulative Incidence of ECMO|Cumulative Incidence of hypotension requiring vasopressor support|SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT|Change in Alanine Aminotransferase (ALT) levels|Change in Aspartate Aminotransferase (AST) levels|Change in Creatinine levels|Change in Glucose levels|Change in White Blood Cell (WBC) count|Change in Hemoglobin levels|Change in Platelet count|Change in total bilirubin levels|Change in Lactate Dehydrogenase (LDH) levels|Change in C-Reactive Protein (CRP) levels|Change in Interleukin 6 (IL-6) levels","NYU Langone Health|State University of New York - Downstate Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","626","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","20-00463","April 15, 2020","June 2021","June 2021","April 30, 2020",,"July 2, 2020","State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04369742"
186,"NCT04340050","COVID-19 Convalescent Plasma",,"Active, not recruiting","No Results Available","Coronavirus","Biological: anti-SARS-CoV-2 convalescent plasma","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0523","April 10, 2020","December 31, 2020","December 31, 2021","April 9, 2020",,"May 14, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04340050"
187,"NCT04379375","Nudges to Improve Health Behaviors That Limit COVID-19 Spread",,"Terminated","No Results Available","Health Behavior|COVID-19","Behavioral: Nudge","Hand Washing Behavior|Clinical Outcomes - General/Internal Medicine|Clinical Outcomes - Obstetrics & Gynecology|Clinical Outcomes - Surgery","Medical College of Wisconsin|Advancing a Healthier Wisconsin Endowment","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO00037864","July 27, 2020","September 30, 2020","September 30, 2020","May 7, 2020",,"October 5, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04379375"
188,"NCT04433078","RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM","STORM","Recruiting","No Results Available","Cytokine Storm|SARS-CoV-2","Drug: Doxycycline|Drug: Placebo","Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death|NP SARS-CoV-2 PCR|SARS-CoV-2 Serum Quantitative Viral Load|SARS-CoV-2 IgM/IgG Antibodies|White Blood Cell Count (WBC)|Absolute Lymphocyte Count (ALC)|C-Reactive Protein (CRP)|N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)|High Sensitivity Troponin I (hsTnT)|Tumor Necrosis Factor Alpha (TNF-a)|IL-1|IL-1B|IL-6","Temple University","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The STORM Trial","June 22, 2020","January 2021","July 2021","June 16, 2020",,"June 24, 2020","Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04433078"
189,"NCT04341675","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","SCOPE","Recruiting","No Results Available","COVID-19","Drug: Sirolimus|Drug: Placebo","Proportion of patients who are alive and free from advanced respiratory support measures at day 28.|Proportion of patients who require escalation in care|Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)|Proportion of patients surviving to hospital discharge|Drug safety profile|Duration of advanced respiratory support|Duration of hospital stay|Time from treatment initiation to death|Time to resolution of fever|Proportion of patients who require initiation of off-label therapies","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0337","April 24, 2020","July 2020","September 2020","April 10, 2020",,"May 20, 2020","Loyola University Medical Center, Chicago, Illinois, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04341675"
190,"NCT04355143","Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)","COLHEART-19","Recruiting","No Results Available","COVID-19","Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians","Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)|Delta (peak minus baseline) troponin level|Delta (baseline to peak) brain natriuretic peptide (BNP) level|Change in left ventricular ejection fraction (LVEF) on echocardiography|Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level|Delta (peak minus baseline) D-Dimer inflammatory biomarker level|Time (days) to primary endpoint|Number of participants requiring mechanical ventilation|Number of participants requiring mechanical circulatory support (MCS)|Re-hospitalization at 90 days|All-cause mortality","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000685","May 1, 2020","April 25, 2021","April 25, 2021","April 21, 2020",,"May 21, 2020","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|UCLA Santa Monica Hospital, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04355143"
191,"NCT04331366","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","Completed","No Results Available","COVID-19","Device: GO2 PEEP MOUTHPIECE","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00000381","April 8, 2020","August 31, 2020","August 31, 2020","April 2, 2020",,"October 19, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04331366"
192,"NCT04466098","Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen","Masonic Cancer Center, University of Minnesota","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020LS075|MT2020-12","July 30, 2020","December 1, 2021","December 1, 2021","July 10, 2020",,"August 14, 2020","University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04466098"
193,"NCT04367831","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","IMPROVE","Recruiting","No Results Available","COVID-19|Venous Thromboses|Arterial Thrombosis","Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose","Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay","Columbia University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AAAS8980","May 2, 2020","November 2020","April 2021","April 29, 2020",,"May 19, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04367831"
194,"NCT04363450","Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","HCQPreP","Recruiting","No Results Available","COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebo","Incidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infection","Louisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at Lafayette","All","18 Years and older   (Adult, Older Adult)","Phase 3","1700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LSU NO HSC IRB 20-050","April 27, 2020","March 31, 2021","June 1, 2021","April 27, 2020",,"September 2, 2020","Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04363450"
195,"NCT04482686","Trial of Combination Therapy to Treat COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID|Covid-19|Corona Virus Infection|Coronavirus Infection|Coronavirus-19|SARS-CoV2|SARS-CoV Infection","Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C","Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events","ProgenaBiome|Topelia Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PRG-049","September 2020","March 2021","April 2021","July 22, 2020",,"September 21, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04482686"
196,"NCT04482673","Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection","VitD-COVID19","Recruiting","No Results Available","COVID-19|Vitamin D Deficiency|Respiratory Viral Infection","Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo","Change in total circulating 25(OH)D concentration|Change in total circulating 25(OH)D concentration in COVID-19 positives|Change in SARS-CoV-2 antibody titers|Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha|Respiratory symptoms|Signs and symptoms of rhino/sinusitis|NCI Dietary Intake|Charlson Comorbidity survey|Paffenberger Physical Activity Assessment|Perceived stress|Pandemic stress|NEO-Personality Inventory|GrassrootsHealth Monthly Health assessment","Medical University of South Carolina|Grassroots Health Nutrition Institute|ZRT Laboratory","All","50 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","00099939","July 31, 2020","December 31, 2021","December 31, 2021","July 22, 2020",,"August 4, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04482673"
197,"NCT04398290","iNOPulse for COVID-19","NO-COVER","Withdrawn","No Results Available","COVID-19|Hypoxemia|Hypoxemic Respiratory Failure","Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas","Incidence of treatment emergent adverse events|Incidence of adverse events|Incidence of methemoglobinemia|Number of participants with progression of respiratory failure|Time until resolution of hypoxemia|Incidence of mortality|Duration of hospitalization","Roger Alvarez|Bellerophon Therapeutics|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200449","December 1, 2020","June 1, 2021","July 15, 2021","May 21, 2020",,"August 19, 2020","University of Miami Hospitals & Clinics, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04398290"
198,"NCT04392232","A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection",,"Recruiting","No Results Available","Coronavirus|COVID-19|Convalescent Plasma","Drug: Convalescent Plasma","Survival Rate","TriHealth Inc.","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-045","May 5, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"May 20, 2020","Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04392232"
199,"NCT04482712","Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS","RAPA-CARDS","Not yet recruiting","No Results Available","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Respiratory Failure|Sars-CoV2","Drug: Rapamycin|Drug: Placebo","Survival rate|Change in Clinical Status assessed by the World Health Organization (WHO) scale|Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale","The University of Texas Health Science Center at San Antonio|Claude D. Pepper Older Americans Independence Center","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HSC20200489H","October 2020","October 2021","October 2022","July 22, 2020",,"July 22, 2020","University Hospital System, San Antonio, Texas, United States|Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04482712"
200,"NCT04554992","Convalescent Plasma for the Treatment of COVID-19",,"Active, not recruiting","No Results Available","Covid19","Biological: COVID 19 Convalescent Plasma","Cumulative incidence of serious adverse events related to the treatment intervention.|Mortality at Day 28 post-hospital admission.|Legnth of hospital stay|Length of supplemental oxygen requirement.|Length of mechanical ventilation requirement.|Length of ICU stay","The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","Phase 1","350","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00025121","March 20, 2020","June 2022","June 2022","September 18, 2020",,"September 18, 2020","Houston Methodist Hopsital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04554992"
201,"NCT04459702","A Study of Combination Therapies to Treat COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID|COVID-19|Corona Virus Infection|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus-19|SARS-CoV 2|SARS Pneumonia","Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir","Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE","ProgenaBiome|Big Corona Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-043","July 2020","July 2021","December 2021","July 7, 2020",,"July 7, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04459702"
202,"NCT04395716","A Study of ResCure™ to Treat COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID|Covid-19|Corona Virus Infection|Sars-CoV2|Coronavirus-19|SARS Pneumonia|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere","Biological: ResCure™","The rate of recovery of mild or moderate COVID-19 in patients using ResCure™|Reduction or progression of symptomatic days|Assess the safety of ResCure™ via pulse|Assess the safety of ResCure™ via oxygen saturation|Assess the safety of ResCure™ via EKG|Assess Tolerability of ResCure™","ProgenaBiome|Rinati Skin, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRG-048","July 2020","June 2021","November 2021","May 20, 2020",,"July 10, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04395716"
203,"NCT04517396","FEnofibRate as a Metabolic INtervention for COVID-19","FERMIN","Enrolling by invitation","No Results Available","Covid19","Other: Fenofibrate|Other: Placebo|Other: Usual care","Hierarchical composite endpoint|Number of days alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support in the 30 days following randomization|Seven-category ordinal scale","University of Pennsylvania|University of Arizona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","843729","August 18, 2020","August 31, 2021","August 31, 2021","August 18, 2020",,"August 27, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04517396"
204,"NCT04335084","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","HELPCOVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Prevention of COVID-19 symptoms as recorded in a daily diary|Safety as determined by presence or absence of Adverse Events and Serious Adverse Events","ProgenaBiome|DSCS CRO","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PRG-042","June 22, 2020","June 2021","September 2021","April 6, 2020",,"July 20, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04335084"
205,"NCT04397510","Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury",,"Enrolling by invitation","No Results Available","Covid-19|ARDS, Human|Acute Lung Injury","Drug: Heparin|Drug: 0.9% Sodium-chloride","Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events","Frederick Health","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FHHep518","June 1, 2020","December 31, 2020","December 31, 2020","May 21, 2020",,"August 18, 2020","Frederick Health Hospital, Frederick, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04397510"
206,"NCT04381013","Emergency Ventilator Splitting Between Two or More Patients (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19","Device: Emergency Ventilator Splitter","Completion of 1-minute test|Completion of 24-hour test","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","57573","December 2020","January 2021","January 2021","May 8, 2020",,"October 8, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT04381013"
207,"NCT04458948","Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients",,"Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","10000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-156","March 24, 2020","March 24, 2021","March 24, 2025","July 7, 2020",,"July 7, 2020","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04458948/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04458948"
208,"NCT04344561","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","UPSAT","Recruiting","No Results Available","COVID|Hypoxic Respiratory Failure","Other: Postural Positioning","Incidence of Mechanical Ventilation|Number of participants with supplemental oxygen requirements|Mean oxyhemoglobin saturation|Mean Nocturnal Oxyhemoglobin Saturation|Heart Rate|Respiratory Rate|Percentage of time in the assigned position","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00246834","May 25, 2020","May 1, 2021","May 1, 2021","April 14, 2020",,"June 24, 2020","Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04344561"
209,"NCT04570397","Ravulizumab and COVID-19",,"Not yet recruiting","No Results Available","Covid19|Thrombotic Microangiopathies|Acute Kidney Injury","Drug: Ravulizumab","Assess the efficacy of ravulizumab to ameliorate SARS-CoV-2 (COVID-19)-induced acute kidney injury manifesting as thrombotic microangiopathy.|Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19","Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","092420","November 2020","May 2021","November 2021","September 30, 2020",,"September 30, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04570397"
210,"NCT04338009","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","REPLACECOVID","Enrolling by invitation","No Results Available","COVID-19","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres","All","18 Years and older   (Adult, Older Adult)","Not Applicable","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","842810","March 31, 2020","December 31, 2020","December 31, 2020","April 8, 2020",,"April 24, 2020","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04338009"
211,"NCT04498442","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",,"Recruiting","No Results Available","Covid19|Stress|Anxiety Depression","Behavioral: Simha Kriya|Behavioral: Reading a Book","Change in Perceived Stress Levels|Changes in Resilience Levels|Changes in Covid-19 Prevalence|Changes in self-reported duration of fever and respiratory symptoms in COVID-19 positive participants|Changes in self-reported readiness to return to work in COVID-19 positive participants","Beth Israel Deaconess Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020P000433","May 22, 2020","October 31, 2020","December 31, 2020","August 4, 2020",,"October 8, 2020","Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04498442"
212,"NCT04354155","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial",,"Recruiting","No Results Available","Infection Viral|Thromboses, Venous|COVID-19","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Safety of in-hospital thromboprophylaxis|Median twice-daily enoxaparin dose","Neil Goldenberg|Johns Hopkins All Children's Hospital","All","up to 18 Years   (Child, Adult)","Phase 2","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVAC-TP","June 2, 2020","September 2022","October 15, 2022","April 21, 2020",,"July 27, 2020","Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04354155"
213,"NCT04495842","The Effect of Aromatherapy on COVID-19-induced Anxiety",,"Recruiting","No Results Available","Stress|Covid19|Anxiety","Other: Essential Oil Blend|Other: Control Blend","Change from baseline in state anxiety on the State portion of the State Trait Anxiety Scale (STAI-S) at 15 minutes","Franklin School of Integrative Health Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","20-7-5600","October 1, 2020","March 31, 2021","June 30, 2021","August 3, 2020",,"October 19, 2020","Franklin School of Integrative Health Sciences, Franklin, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04495842"
214,"NCT04531618","Mother-infant Bonding During COVID-19",,"Recruiting","No Results Available","Child Development|Mother-Infant Interaction|COVID-19","Behavioral: Family Nurture Intervention (FNI)","Change in Welch Emotional Connection Score|Change in Maternal Caregiving Behavior Score (Acceptance versus Rejection)|Change in Maternal Caregiving Behavior Score (Sensitivity versus Insensitivity)|Change in Maternal Caregiving Behavior Score (Consideration versus Intrusiveness)|Change in Maternal Caregiving Behavior Score (Quality of Physical Contact)|Change in Maternal Caregiving Behavior Score (Quality of Vocal Contact)|Change in Maternal Caregiving Behavior Score (Effectiveness of Response to Baby's Crying)|Right and Left Frontal Mother & Infant EEG Synchrony|Heart Rate Variability (HRV)","Columbia University","All","up to 72 Hours   (Child)","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AAAT0140","August 13, 2020","December 2021","December 2021","August 28, 2020",,"August 31, 2020","Morgan Stanley Children's Hopspital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04531618"
215,"NCT04379661","SUNLIGHT Study: Online Support Groups for MS to Address COVID-19",,"Recruiting","No Results Available","MS (Multiple Sclerosis)|COVID-19|Support Groups","Behavioral: Online support Group","Rate of completion|Rate of adherence|Score on the State Trait Anxiety Inventory (STAI)|Score on the Personal Health Questionnaire Depression Scale (PHQ-8)","Columbia University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAAS9939","April 3, 2020","April 2021","April 2021","May 7, 2020",,"May 7, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04379661"
216,"NCT04513314","Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium",,"Not yet recruiting","No Results Available","Covid19|Hyperactive Delirium|Pneumonia, Viral","Drug: Valproate|Drug: Quetiapine|Other: Standard of Care","Change from baseline RASS score of +3 or greater|Total dose of dexmedetomidine administered|Incidence of Treatment Emergent Adverse Events","University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","20200851","November 1, 2020","November 1, 2021","November 1, 2021","August 14, 2020",,"September 21, 2020","Jackson Memorial Hospital, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04513314"
217,"NCT04409834","Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","COVID-PACT","Recruiting","No Results Available","COVID-19|Venous Thromboembolism|Arterial Thrombosis","Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution","Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events","The TIMI Study Group","All","18 Years and older   (Adult, Older Adult)","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CCCTN/TIMI COVID-PACT","August 5, 2020","May 2021","May 2021","June 1, 2020",,"August 18, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04409834"
218,"NCT04305457","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NoCovid","Active, not recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Massachusetts General Hospital|University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NOgas mildCOVID-19","March 21, 2020","April 1, 2021","April 1, 2022","March 12, 2020",,"August 31, 2020","Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04305457"
219,"NCT04473274","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GOTCHA","Recruiting","No Results Available","Coronavirus Infection|Diabetes","Drug: Pioglitazone","Adverse events outcomes without attribution|Adverse events attributable|Clinical improvement|Levels of treatment|d-Dimer|C Reactive Protein|Ferritin|Lactate dehydrogenase|A1c","Samaritan Health Services","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-042","May 21, 2020","June 1, 2021","June 1, 2021","July 16, 2020",,"July 20, 2020","Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04473274"
220,"NCT04325906","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS",,"Recruiting","No Results Available","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Treatment failure|Intubation rate|Efficacy of PP","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-HFNC+PP","April 2, 2020","November 30, 2020","December 31, 2020","March 30, 2020",,"October 6, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04325906"
221,"NCT04376034","Convalescent Plasma Collection and Treatment in Pediatrics and Adults",,"Recruiting","No Results Available","COVID19|Coronavirus Infection|Coronavirus|Virus Diseases|RNA Virus Infections","Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care","Plasma Donor|Plasma Recipient","West Virginia University","All","31 Days and older   (Child, Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004965705","April 16, 2020","March 30, 2021","March 30, 2021","May 6, 2020",,"May 6, 2020","WVU Medicine, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04376034"
222,"NCT04455958","Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year",,"Not yet recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Symptomatic COVID-19 Infection Laboratory-Confirmed","Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration","Severity of symptoms|Clinical benefit rate of lopinavir/ritonavir|Time to symptom progression|Time to improvement of participants|Time to hospital admission for those who develop severe of critical symptoms|Intensive care unit (ICU) admission: yes or no|Receiving ventilator support: yes or no|Overall survival","OHSU Knight Cancer Institute|Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STUDY00021444|NCI-2020-02877","November 1, 2020","November 1, 2021","November 1, 2021","July 2, 2020",,"September 18, 2020","OHSU Knight Cancer Institute, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04455958"
223,"NCT04371419","COVID-19 Health Messaging to Underserved Communities",,"Completed","No Results Available","Coronavirus","Behavioral: Messaging","Knowledge Beliefs and Practices related to COVID-19|Video Ratings","National Bureau of Economic Research, Inc.|Massachusetts General Hospital|Stanford University|Yale University|Massachusetts Institute of Technology|Harvard University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15475","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2003000118","May 13, 2020","May 24, 2020","May 24, 2020","May 1, 2020",,"June 19, 2020","JPAL North America, Cambridge, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04371419/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04371419"
224,"NCT04581811","Prolonged Prone Positioning for COVID-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study",,"Not yet recruiting","No Results Available","ARDS|Covid19|Acute Hypoxemic Respiratory Failure","Other: Prolonged Proned Positioning|Other: Traditional Proning Arm","Duration in prone position|Change in P:F ratio|Drive Pressure|Unplanned extubations|Pressure ulcers|Line displacement|Duration of mechanical ventilation|Mortality|Rescue Interventions","University of Alabama at Birmingham","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300005979","January 2021","May 2021","June 2021","October 9, 2020",,"October 9, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04581811"
225,"NCT04592705","Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients",,"Recruiting","No Results Available","COVID-19","Device: Therapeutic plasma exchange","Time to clinical status downgrade or discharge.","Larkin Community Hospital","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","LCH-1-092020","September 11, 2020","August 30, 2021","August 30, 2021","October 19, 2020",,"October 19, 2020","Larkin Community Hospital, South Miami, Florida, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04592705/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04592705"
226,"NCT04415879","Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.",,"Completed","No Results Available","COVID-19","Device: N-95 Respirator|Device: Cloth Face Mask|Diagnostic Test: Graded exercise test","Exercise Capacity","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20-538","June 1, 2020","August 1, 2020","August 1, 2020","June 4, 2020",,"August 13, 2020","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04415879"
227,"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",,"Active, not recruiting","No Results Available","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009414","April 6, 2020","August 2020","August 2020","March 31, 2020",,"May 27, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04328467"
228,"NCT04352946","HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","HERO","Not yet recruiting","No Results Available","Prophylaxis|COVID-19|Health Care Worker|Hydroxychloroquine","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet","Cumulative Incidence of COVID-19 Infection|Adverse events incidence|Duration of symptomatic COVID-19 disease|Days hospitalized attributed to COVID-19|Number or respiratory failure attributable to COVID-19 disease|Mortality Incidence|Days of work lost","GeoSentinel Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GFICOVID-19-1","April 24, 2020","June 24, 2020","August 24, 2020","April 20, 2020",,"April 22, 2020","The New York Center for Travel and Tropical Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04352946"
229,"NCT04369599","Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19",,"Enrolling by invitation","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Device: V/Q Vest","Change in Arterial Oxygenation Levels|Number of participants requiring advanced therapy|Number of participants avoiding proning ventilation|Number of participants delaying proning ventilation","Emory University|Georgia Tech Research Foundation|Georgia Clinical & Translational Science Alliance","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000402","August 11, 2020","April 2021","April 2021","April 30, 2020",,"September 16, 2020","Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04369599"
230,"NCT04411602","Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD",,"Recruiting","No Results Available","Severe Acute Respiratory Syndrome|COVID","Drug: SARS-CoV-2 plasma","Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.|Ventilatory free days|Patient mortality (including death from any cause)","Ascension South East Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1589349","April 7, 2020","December 31, 2020","December 31, 2020","June 2, 2020",,"June 2, 2020","Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04411602"
231,"NCT04412330","Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19","OPTIMAL","Recruiting","No Results Available","Covid-19|Critical Illness|Post Intensive Care Unit Syndrome|Muscle Weakness","Other: ICU Recovery + Physical Therapy","Adverse events (safety)|Feasibility (success of consent process, adherence, and attrition)|Six minute walk test|Short Performance Physical Battery|Quality of life (EQ-5DL)|Cognitive function|Anxiety and Depression|PTSD and distress|Return to work|Secondary complication","University of Kentucky|Ashley Montgomery-Yates","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","59097","May 1, 2020","May 1, 2021","May 1, 2021","June 2, 2020",,"June 24, 2020","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04412330"
232,"NCT04319445","Mindfulness During COVID-19",,"Recruiting","No Results Available","Migraine Disorders|Stress|Anxiety","Behavioral: Mindfulness session(s)","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","Wake Forest University Health Sciences","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00064587","March 22, 2020","December 2020","December 2020","March 24, 2020",,"April 24, 2020","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04319445"
233,"NCT04421404","Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","CAPRI","Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo","Mechanical Ventilation or Death Endpoint|8-Point Ordinal Scale Endpoint","Priscilla Hsue, MD|Blood Systems Research Institute|San Francisco General Hospital|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-30794","June 9, 2020","April 30, 2021","April 30, 2021","June 9, 2020",,"August 6, 2020","San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04421404"
234,"NCT04344184","Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)",,"Not yet recruiting","No Results Available","COVID-19|Lung Injury, Acute","Drug: L-ascorbic acid|Other: Placebo","Number of ventilator-free days|All-cause-mortality|Acute-inflammation-free days|Organ-failure-free days","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20018977","October 2020","May 2021","May 2021","April 14, 2020",,"July 22, 2020","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04344184"
235,"NCT04414371","Tools for Wellbeing COVID-19 National Study of Undergraduate Students",,"Recruiting","No Results Available","Stress|Anxiety|Depression|Resilience|Wellbeing|Mood","Other: Yoga","Stress|Wellbeing|Anxiety|Depression|Resilience|Positive Affect|Negative Affect","Rutgers, The State University of New Jersey|Harvard Medical School","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro2020000953","May 20, 2020","December 31, 2020","December 31, 2020","June 4, 2020",,"June 4, 2020","Rutgers University, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04414371"
236,"NCT04406064","Viral Specific T-cells for Treatment of COVID-19",,"Not yet recruiting","No Results Available","Viral Infection","Biological: Viral Specific T-cells (VSTs)","Successful production of viral specific T-cells|Presence of viral-specific T-cells","Children's Hospital Medical Center, Cincinnati|Hoxworth Blood Center","All","Child, Adult, Older Adult","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0353","September 2020","June 2024","June 2025","May 28, 2020",,"July 23, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04406064"
237,"NCT04431856","CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment","Co-PARENT","Recruiting","No Results Available","Anxiety|Depression|Traumatic Stress Disorder","Behavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHG","Measure of Anxiety as assessed by the OASIS|Measure of Depression as assessed by the ODSIS|Measure of PTSD as assessed by the PCL-5|Measure of Parenting Overprotection/Overcontrol as assessed by the S-EMBU|Measure of Parenting Rejection as assessed by the S-EMBU|Measure of Parenting Emotional Warmth as assessed by the S-EMBU|Measure of Parent Accommodation for Child Anxiety as assessed by the FASA","University of Miami","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20200484","May 15, 2020","November 7, 2020","November 7, 2020","June 16, 2020",,"July 8, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04431856"
238,"NCT04486144","Impact Nerium Oleander on Symptoms and Mortality: A Feasibility Study",,"Enrolling by invitation","No Results Available","Covid19 Positive Patient|Covid19 Close Contact","Other: Proprietary extract of Nerium oleander","COVID19 symptoms|Mortality|COVID19 Live Virus|RT-PCR COVID19 Test","HealthQuilt|The Schull Institute|Texas A&M University|The Hildebrand Fund at the Greater Houston Community Foundation|Baylor College of Medicine|The University of Texas Health Science Center, Houston|University of Maryland, College Park","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","052020","May 20, 2020","September 1, 2020","September 1, 2020","July 24, 2020",,"July 24, 2020","KDunn and Associates, PA, dba Healthquilt, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04486144"
239,"NCT04490239","Intranasal Heparin Tolerability Study",,"Active, not recruiting","No Results Available","Covid19","Drug: Intranasal heparin sodium (porcine)","activated partial thromboplastin time (aPTT), acute phase|activated partial thromboplastin time (aPTT), chronic phase|platelet count, acute phase|platelet count, chronic phase|Number of incidents of epistaxis, acute phase|Number of incidents of epistaxis, chronic phase|Other adverse effects, acute phase|Other adverse effects, chronic phase","Joshua Sharp|University of Mississippi, Oxford","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intranasal Heparin","October 9, 2020","November 2020","November 2020","July 29, 2020",,"October 14, 2020","The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT04490239"
240,"NCT04399252","Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19",,"Recruiting","No Results Available","Microbiome","Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo","Change in Shannon Diversity|Change in Shannon Diversity in patients that develop COVID-19","Duke University","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Pro00105674","June 24, 2020","May 25, 2022","May 25, 2022","May 22, 2020",,"July 1, 2020","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04399252"
241,"NCT04329533","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic",,"Recruiting","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance","Other: ""Calm"" is a mindfulness meditation mobile app","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","University of Arizona","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2003524869","April 13, 2020","June 30, 2020","July 30, 2020","April 1, 2020",,"June 19, 2020","Banner University Medicine Women's Institute, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04329533"
242,"NCT04374786","Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic",,"Enrolling by invitation","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance|Burnout|PTSD","Device: Calm Meditation App","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Impact of Event Scale-6|Maslach Burnout Inventory|Adherence|Coronavirus Questionnaire|Participant Satisfaction","University of Arizona","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","328","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2003524869 [Sub-study]","May 15, 2020","September 1, 2020","October 1, 2020","May 5, 2020",,"June 4, 2020","Banner University Medical Center Phoenix, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04374786"
243,"NCT04418518","A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness","CONCOR-1","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)","Weill Medical College of Cornell University|Hamilton Health Sciences Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-04021981","June 24, 2020","June 2021","December 2021","June 5, 2020",,"July 7, 2020","Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lower Manhattan Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04418518"
244,"NCT04326452","Treating COVID-19 With a Bidirectional Oxygenation Valve",,"Recruiting","No Results Available","Coronavirus Infection","Device: bidirectional oxygenation mouthpiece","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","TMC HealthCare|PEEP Medical, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19PEEP2020|GO2 PEEP Study","March 27, 2020","March 27, 2021","March 27, 2021","March 30, 2020",,"October 6, 2020","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04326452"
245,"NCT04373135","Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","UC-COVID","Active, not recruiting","No Results Available","Covid-19|Critical Illness|Attitude of Health Personnel|Attitude to Health|Health Behavior|Health Care Utilization","Behavioral: Brief educational video","Improvement in knowledge surrounding SRA policy|Improvement in anxiety surrounding SRA policy|Improvement in trust surrounding SRA policy","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UCLA-20-000683","May 8, 2020","February 2021","March 2021","May 4, 2020",,"October 14, 2020","University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04373135"
246,"NCT04441996","Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity",,"Enrolling by invitation","No Results Available","COVID-19","Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care","Change in Plasma Viscosity|All Cause Mortality|Bleeding and Thromboembolic Complications|Time to Treatment Failure|Duration of ICU Stay|Duration of Hospital Stay|Discharge Disposition|Change in Clinical Status|Change in Body Temperature|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate|Change in Respiratory Rate|Change in Ventilator Days|Change in Ventilator Oxygen Percent (FiO2)|Change in Positive End-Expiratory Pressure (PEEP)|Change in Vasopressor Requirements|Change in Need for Treatment from a Registered Respiratory Therapist (RRT)|Change in Sequential Organ Failure Assessment (SOFA) Score|Change in Partial Pressure of Arterial Oxygen (PaO2)/Percentage of Inspired Oxygen (FiO2) Ratio|Change in Ventilatory Ratio|Change in White Blood Count (WBC)|Change in Hemoglobin (Hb)|Change in Hematocrit (Hct)|Change in Platelet Count|Change in Mean Platelet Volume (MVP)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Bilirubin|Change in Total Protein|Change in Albumin|Change in C-reactive Protein (CRP)|Change in Interleukin 6 (IL-6)|Change in Prothrombin Time (PT)|Change in International Normalized Ratio (INR)|Change in Activated Partial Thromboplastin Time (aPTT)|Change in Anti-factor Xa (anti-Xa)|Change in Fibrinogen|Change in D-dimer","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000949","July 17, 2020","October 2020","October 2020","June 22, 2020",,"July 22, 2020","Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04441996"
247,"NCT04424797","Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol",,"Recruiting","No Results Available","COVID-19","Other: Prone Positioning|Other: Supine Positioning","Incidence of intubation|Maximum oxygen requirement|Length of Stay|Ventilator-free days|Treatment failure of prone positioning due to worsening SpO2 status while prone|Mortality","Poudre Valley Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-6034","July 13, 2020","December 2020","December 2020","June 11, 2020",,"July 16, 2020","UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|UCHealth Medical Center of the Rockies, Loveland, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04424797"
248,"NCT04548531","Engaging Patients in Colon Cancer Screening Decisions During COVID-19",,"Enrolling by invitation","No Results Available","Colon Cancer","Behavioral: Shared Decision Making","Shared Decision Making (SDM) Process Scale Score|Decisional Conflict (SURE scale)|Patient's preferred approach to screening|Intention to screen|Colon cancer screening rate","Massachusetts General Hospital|Patient-Centered Outcomes Research Institute","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","2020P001579-2","September 10, 2020","April 30, 2021","May 30, 2021","September 14, 2020",,"September 30, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04548531"
249,"NCT04459455","Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",,"Completed","No Results Available","Anxiety","Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI","Change in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention|Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up|Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention|COVID-19 Related Questions|Inventory of Depression and Anxiety Symptoms (IDAS)|Self Hate Scale (SHS)|Comprehension Questions|Everyday Discrimination Scale-Short version|Perceived Changes in generalized anxiety symptoms|Activity Hand Washing Intentions - 3 item version (WASH-I)","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB2020-00204","August 19, 2020","October 15, 2020","October 15, 2020","July 7, 2020",,"October 20, 2020","Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT04459455"
250,"NCT04409743","Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic",,"Recruiting","No Results Available","Sleep Disturbance|Insomnia","Behavioral: Remote Cognitive Behavioral Therapy for Insomnia","Change in Insomnia Clinical Diagnosis|Change in Beck Depression Inventory-II (BDI) Scale Score|Change in Beck Anxiety Inventory (BAI) Scale Score|Change in Quality of Life (SF-36) Scale Score|Change in Sheehan Suicidality Tracking Scale (S-STS) Score|Change in Ford Insomnia Response to Stress Test (FIRST) Scale Score|Change in UCLA Loneliness Scale Score|Change in Social Network Index (SNI) Scale Score|Change in Perceived Stress Scale Score|Change in Screen Time- Self Report|Change in International Physical Activity Questionnaire (IPAQ) Scale Score|Change in Sleep Onset Latency (SOL) as a Measure of Sleep Continuity|Change in Number of Arousals as a Measure of Sleep Continuity|Change in Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity|Change in Total Sleep Time (TST) as a Measure of Sleep Continuity|Change in Sleep Efficiency (SE) as a Measure of Sleep Continuity|Change in Insomnia Severity Index (ISI) Scale Score|Change in Patient Health Questionnaire-9 (PHQ-9) Scale Score as a Measure of Depression Symptoms|Change in Generalized Anxiety Disorder-7 (GAD-7) Scale Score","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB-55940","June 7, 2020","May 2021","November 2021","June 1, 2020",,"July 21, 2020","Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04409743"
251,"NCT04349332","Early Extubation for Patients With Acute Hypoxemic Respiratory Failure",,"Not yet recruiting","No Results Available","Mechanical Ventilation|Corona Virus Infection","Device: Helmet non-invasive ventilation (NIV)","ventilator days|Intensive care unit (ICU) length of stay|need for re-intubation","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20-0594","May 15, 2020","April 1, 2021","June 1, 2021","April 16, 2020",,"April 30, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04349332"
252,"NCT04555122","COVID-19 Ad Intervention",,"Not yet recruiting","No Results Available","Social Distance","Behavioral: Social Distancing Advertisements","Mobility","University of California, Irvine|City University of Hong Kong|University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","52500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","COVID-Ad","September 29, 2020","May 28, 2022","July 28, 2022","September 18, 2020",,"September 23, 2020","UC Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT04555122"
253,"NCT04426318","COVID-19 and the Healthy Minds Program for Educators","CAHMP-ED","Recruiting","No Results Available","Anxiety|Depression|Psychological Stress|Psychological Distress|Well-being","Behavioral: Healthy Minds Program Foundations Training","Change from baseline on an aggregate measure of Psychological distress that averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depressive Measures and the NIH Perceived Stress Scale|Change from baseline on the Five Facet Mindfulness Questionnaire Act with Awareness subscale|Change from baseline on the Drexel Defusion Scale (DDS)|Change from baseline on the Meaning in Life Questionnaire|Change from baseline on the NIH Toolbox Loneliness scale|Change from baseline on the Conway COVID Questionnaire|Change from baseline on the Self-Compassion Scale Short Form|Change from baseline on the Perseverative Thought Questionnaire|Change from baseline on the World Health Organization 5-item (WHO-5) well-being scale|Change from baseline on the Neutral Face Rating task|Change from baseline on the Growth Mindset Scale for Well-Being","University of Wisconsin, Madison|Chan Zuckerberg Initiative|Healthy Minds Innovations|Center for Healthy Minds","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","2020-0533|A171600|EDUC/COUNSELING PSYCH|Protocol Approval 6/4/2020","June 14, 2020","January 30, 2021","June 30, 2022","June 11, 2020",,"July 1, 2020","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04426318"
254,"NCT04497415","The COVID-19 and Healthcare Workers: An Active Intervention",,"Not yet recruiting","No Results Available","Brief Video-based Intervention|Non Intervention Control","Other: Video-Based intervention","Help-seeking behavior|GAD-7|PHQ-9|PC-PTSD|Moral Injury","Research Foundation for Mental Hygiene, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","8032","October 10, 2020","November 30, 2020","January 30, 2021","August 4, 2020",,"October 8, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04497415"
255,"NCT04370938","Provider Burnout During COVID-19",,"Recruiting","No Results Available","Perceived Organizational Support, Anxiety, Burnout","Behavioral: Coping strategies video","Feasibility of undertaking task","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","STUDY20040051","April 29, 2020","October 29, 2020","October 29, 2020","May 1, 2020",,"May 1, 2020","UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04370938"
256,"NCT04484207","Addressing COVID-19 Mental Health Problems Among US Veterans",,"Recruiting","No Results Available","Brief Video-based Intervention|Vignette Based Intervention|Non Intervention Control Arm","Other: A short video intervention|Other: A vignette intervention","Help seeking behavior|Generalized Anxiety Disorder (GAD-7)|Patient Health Questionnaire-9|The Primary Care PTSD Screen for DSM-5 (PC-PTSD)","Research Foundation for Mental Hygiene, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","8006","July 6, 2020","October 20, 2020","October 26, 2020","July 23, 2020",,"October 14, 2020","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04484207"
257,"NCT04376515","Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19)",,"Active, not recruiting","No Results Available","Anxiety","Behavioral: HOPE intervention","Anxiety","University of California, Irvine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","UCaliforniaIrvineSYoung","March 20, 2020","June 1, 2020","September 1, 2020","May 6, 2020",,"May 6, 2020","UC Irvine, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT04376515"
258,"NCT04464486","Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic",,"Enrolling by invitation","No Results Available","Oncology","Other: SCH Intervention","Health Care Utilization Comparison|Patient Social Isolation|COVID-19 Symptoms, Social distancing and Hygiene Practices|Patient Global Health|Patient Anxiety/Depression|Impact of Pandemic and Health Related Quality of Life|Cancer symptom severity","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB_00131892","April 21, 2020","March 31, 2021","May 31, 2021","July 9, 2020",,"July 9, 2020","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04464486"
259,"NCT04501445","Psychological Symptoms and Families of COVID-19 Patients",,"Recruiting","No Results Available","Family Members|Post Intensive Care Unit Syndrome|Post Traumatic Stress Disorder","Behavioral: Written Summary of Rounds","Symptoms of Post-Traumatic Stress Disorder (PTSD) initial|Symptoms of Anxiety and Depression initial|Surrogate Satisfaction with the Patient's ICU Care:|Symptoms of Post-Traumatic Stress Disorder (PTSD) final|Symptoms of Anxiety and Depression final|Interview initial|Interview final","Rush University Medical Center|Central Michigan University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20071101","September 14, 2020","August 1, 2021","September 15, 2021","August 6, 2020",,"October 8, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04501445"
260,"NCT04431297","Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic",,"Not yet recruiting","No Results Available","Chronic Stress","Other: Mindfulness Rounds","Change in Perceived Stress Scale","Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","GCO 20-1022","September 1, 2020","December 2020","June 2021","June 16, 2020",,"July 31, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04431297"
261,"NCT04460677","ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19",,"Recruiting","No Results Available","Psychological Distress|Stress, Psychological|Autism Spectrum Disorder","Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring","Decreased distress on Patient Health Questionnaire (PHQ-9)|Decreased distress on EMA reports|Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)|Adult Self Report (ASR)","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020001593","August 12, 2020","March 31, 2021","March 31, 2021","July 7, 2020",,"September 9, 2020","Rutgers University, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04460677"
262,"NCT04417270","Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge",,"Recruiting","No Results Available","Diabetes Mellitus","Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform","Comparison of values between two devices","Northwell Health","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-0455","June 12, 2020","September 30, 2020","October 31, 2020","June 4, 2020",,"July 8, 2020","Lenox Hill Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04417270"
263,"NCT04453514","Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic",,"Recruiting","No Results Available","Anxiety","Behavioral: Trauma-informed yoga video recording","Number of participants enrolled over 3 months|Number of participants enrolled per week over 3 months|Proportion of participants who enroll in the study over 3 months|Proportion of participants who complete the study over 3 months|Proportion of missing data over 3 months|Proportion of participants who complete the 45-minute video over 3 months|Mean change in state anxiety from immediately before to immediately after yoga using the State Trait Anxiety Scale - 6 item short form|Mean change in state mindfulness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Mind subscale)|Mean change in body awareness from immediately before to immediately after yoga using the State Mindfulness Scale (State Mindfulness of Body subscale)","National University of Natural Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Tibbitts_TIYoga_COVID","July 21, 2020","October 2020","October 2020","July 1, 2020",,"July 24, 2020","National University of Natural Medicine, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04453514"
264,"NCT04551339","Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19","ZnCOVID-19","Enrolling by invitation","No Results Available","Healthy|Health Care Worker Patient Transmission|Aging","Dietary Supplement: PreserVision AREDS formulation gel tabs|Dietary Supplement: Centrum Adult (under 50) multivitamin","COVID-19 illness requiring hospitalization|Illness without hospitalization|Supplemental oxygen therapy during hospitalization|Invasive ventilation during hospitalization|Mortality","Mayo Clinic","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","4500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-004637","September 28, 2020","March 14, 2021","May 14, 2021","September 16, 2020",,"September 29, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04551339"
265,"NCT04558411","Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",,"Recruiting","No Results Available","Emotional Regulation|Affect","Behavioral: Dialectical Behavioral Therapy (DBT) Skills","Distress|Emotion regulation|Distress (within-person change)|Maintenance of improvement in emotion regulation","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro2020002008","September 12, 2020","December 15, 2020","December 15, 2020","September 22, 2020",,"September 22, 2020","Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04558411"
266,"NCT04519216","Breastfeeding Education in the Time of COVID-19",,"Recruiting","No Results Available","Breastfeeding|Breastfeeding, Exclusive|Breastfeeding Jaundice|Educational Problems","Behavioral: Telesimulation","Change in practice patterns|Self efficacy|Satisfaction with simulation","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","1613611-2","July 31, 2020","June 30, 2021","September 30, 2021","August 19, 2020",,"August 19, 2020","University of California - Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04519216"
267,"NCT04548544","A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19",,"Completed","No Results Available","Healthy","Behavioral: Training for Awareness, Resilience, and Action (TARA)","Change in Emotional Problems","University of California, San Francisco","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","19-29083 (b)","October 18, 2019","May 20, 2020","May 20, 2020","September 14, 2020",,"September 14, 2020","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04548544"
268,"NCT04530448","Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization",,"Recruiting","No Results Available","COVID|Coronavirus|Coronavirus Infection|AKI|Acute Kidney Injury","Drug: Sodium bicarbonate|Other: Standard of Care","pH|Number of Days Alive Free of Stage 2-3 AKI|Stage 2-3 AKI|Vent-Free|Hospital-Free","West Virginia University","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WVU Protocol #2005006707","October 5, 2020","January 2021","March 2021","August 28, 2020",,"October 19, 2020","WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04530448"
269,"NCT04453657","Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",,"Enrolling by invitation","No Results Available","Stress, Psychological|Child Behavior|Social Competence","Device: FamilyChildCare (provisional name of app)","Change in Perceived Level of Stress as assessed by the Perceived Stress Scale|Change in Perceived Level of Informational Support as assessed by the PROMIS Informational Support Short Form|Change in Awareness of the Maryland Early Childhood Family Engagement Framework and Toolkit as assessed by a survey question|Change in Social, Emotional, and Behavior Functioning in Children as assessed by the Social Competence and Behavior Evaluation for Children|Change in Quality of the Parent-Child Care Relationship as assessed by the Supportive Parent-Caregiver Relationship Subscale","Johns Hopkins University","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Not Applicable","270","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00250864","October 2020","September 2021","September 2021","July 1, 2020",,"October 19, 2020","Johns Hopkins School of Nursing, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04453657"
270,"NCT04386291","Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19",,"Recruiting","No Results Available","Generalized Anxiety|Health Anxiety","Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training","GAD-7|Whiteley 8|PHQ-8|SS-8|Applied Cognition 1.0|PROMIS-4 Sleep Disturbance|ERQ|Perceived Stress Scale|Brief Hypervigilance Scale","Research Foundation for Mental Hygiene, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7987","May 25, 2020","May 19, 2021","January 30, 2022","May 13, 2020",,"July 1, 2020","ProofPilot (Virtual Study: https://proofpilot.com/covid-anxiety/), New York, New York, United States|Columbia University Department of Psychiatry, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04386291"
271,"NCT04306393","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","NOSARSCOVID","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Drug: Nitric Oxide Gas","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 21, 2020","March 21, 2021","March 21, 2022","March 12, 2020",,"July 14, 2020","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04306393"
272,"NCT04513158","Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection",,"Recruiting","No Results Available","Covid19","Biological: Convalescent Plasma","Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count (10*3/uL)|reatinine kinase (mg/dL)|C-reactive protein (mg/dl)|D-Dimer (ng/ml FEU)|Interleukin-6 (pg/ml)|Ferritin (ng/mL)","Joseph M. Flynn, D.O., MPH|Norton Healthcare","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-N0124","August 14, 2020","August 1, 2021","December 31, 2021","August 14, 2020",,"October 19, 2020","Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04513158"
273,"NCT04335552","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",,"Terminated","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Duke University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00105339","April 17, 2020","June 17, 2020","June 26, 2020","April 6, 2020",,"July 31, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04335552"
274,"NCT04398277","A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic",,"Recruiting","No Results Available","Psychological Stress","Behavioral: Daily Coping Toolkit","Patient Health Questionnaire - 4|World Health Organization Well Being Questionnaire|Affective Experience|Treatment Acceptability Questionnaire","Kent State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20-183","May 1, 2020","April 2021","April 2021","May 21, 2020",,"May 21, 2020","Akron Children's Hospital, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Kent State University, Kent, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04398277"
275,"NCT04340557","Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection",,"Recruiting","No Results Available","SARS-CoV Infection","Drug: Losartan","Mechanical ventilation|ICU transfer|Oxygen therapy","Sharp HealthCare","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVID-ARB|2003902","March 27, 2020","October 6, 2020","December 31, 2020","April 9, 2020",,"June 2, 2020","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04340557"
276,"NCT04419025","Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease",,"Recruiting","No Results Available","COVID|Sars-CoV2|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|Oxidative Stress","Drug: N-acetylcysteine","Decrease in Respiratory Rate|Hospital length of stay (LOS)|Need for mechanical ventilation|Length of time intubated|Need for hospitalization|Recovery disposition","Cambridge Health Alliance","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHA-IRB-1139/05/20","September 23, 2020","January 31, 2021","May 31, 2021","June 5, 2020",,"September 25, 2020","CHA Cambridge Hospital, Cambridge, Massachusetts, United States|CHA Everett Hospital, Everett, Massachusetts, United States|CHA Respiratory Clinic, Somerville, Massachusetts, United States|CHA Somerville campus, Somerville, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04419025"
277,"NCT04341441","Will Hydroxychloroquine Impede or Prevent COVID-19","WHIP COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.","Henry Ford Health System","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1410401","April 7, 2020","June 30, 2020","April 30, 2021","April 10, 2020",,"May 7, 2020","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT04341441"
278,"NCT04311177","Losartan for Patients With COVID-19 Not Requiring Hospitalization",,"Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days","University of Minnesota|The Minnesota Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28683","April 9, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"June 16, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04311177"
279,"NCT04473599","Stay Well at Home: a Text-messaging Study Social Distancing",,"Recruiting","No Results Available","Depressive Symptoms|Anxiety|COVID-19","Behavioral: Uniform random message delivery|Behavioral: Reinforcement learning message delivery","Depression scores|Anxiety scores|Self reported mood ratings","University of California, Berkeley","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2020-04-13162","April 17, 2020","April 1, 2021","April 1, 2021","July 16, 2020",,"July 28, 2020","University of California Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT04473599"
280,"NCT04160975","Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects",,"Enrolling by invitation","No Results Available","Flu, Human|Influenza, Human|Covid19","Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination|Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy","Posterior beliefs about the risk/benefits of the flu shot|Demand for information about a COVID-19 vaccine|Willingness-to-pay (WTP) for a free flu shot coupon|Level of attention and recall from the infomercial video during Baseline survey|Level of attention and recall from the infomercial video during Endline survey|Redemption of said coupon","Harvard University|Stanford University|Massachusetts Institute of Technology","Male","18 Years to 51 Years   (Adult)","Not Applicable","3350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research","IRB19-1424","December 20, 2019","February 15, 2021","February 15, 2021","November 13, 2019",,"October 14, 2020","Harvard University, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04160975"
281,"NCT04441632","Effect of Positive Attitudes on Behavior and Wellness","TEAM-ICU","Completed","No Results Available","Burnout|Stress, Emotional","Behavioral: Positive feedback","Teamwork climate, as measured by selected items from the validated Safety Attitude Questionnaire (SAQ)|Resiliency, as measured by the validated Brief Resilience Scale (BRS)|Burnout, as validated by the single-item burnout scale inventory","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000786","June 15, 2020","July 26, 2020","July 30, 2020","June 22, 2020",,"August 12, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04441632"
282,"NCT04370262","Multi-site Adaptive Trials for COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo","Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","942","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0268","April 7, 2020","September 7, 2020","April 7, 2021","April 30, 2020",,"June 16, 2020","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370262"
283,"NCT04514900","Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program","iREACH","Recruiting","No Results Available","Obesity","Behavioral: Video Chat +Personalized Feedback|Behavioral: Video Chat + Basic Feedback|Behavioral: Discussion Board for Social Support +Basic Feedback|Behavioral: Discussion Board for Social Support+Personalized Feedback","Weight loss|Change in body weight from baseline calculated as % of body weight lost|Treatment Engagement: daily weighing|Treatment Engagement: weekly food journal submissions|Treatment Engagement: completion of the 16 weekly interactive online modules|Treatment Engagement: Attendance at Video Chat condition","University of South Carolina|University of Vermont|University of Tennessee","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00101006","September 23, 2020","September 15, 2021","September 15, 2021","August 17, 2020",,"September 30, 2020","University of South Carolina, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04514900"
284,"NCT04480112","Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults",,"Enrolling by invitation","No Results Available","Memory Disorders|Alzheimer Disease|Mild Cognitive Impairment","Behavioral: Technology based social interactions|Other: No research related technology based social interactions","Change in memory performance|Change in cognition|Change in phonemic fluency|Social isolation|Loneliness|Depressive symptoms|Misinformation about Covid-19","Boston University","All","Child, Adult, Older Adult","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","H-26786","June 2, 2020","May 2021","May 2021","July 21, 2020",,"September 4, 2020","Boston University Alzheimer Disease Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04480112"
285,"NCT04420273","Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access","TMD","Active, not recruiting","No Results Available","Melanoma","Behavioral: SSE educational intervention|Other: Home sample collection of concerning mole with physician supervision|Behavioral: Active control:Healthy Living","Change in SSE performance|Identification of concerning mole|Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma|Change in skin self-examination anxiety|Change in confidence performing mole checks|Number of physician visits for concerning moles|Number of biopsies of concerning moles","Northwestern University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","STU00212165","July 2, 2020","March 30, 2021","December 30, 2021","June 9, 2020",,"September 4, 2020","Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04420273"
286,"NCT04490278","CoV-PICS: A Virtual Post-ICU Clinic",,"Recruiting","No Results Available","Post ICU Syndrome","Other: Medical Record Review - Inpatient Treatment|Other: Online Questionnaires","Acceptance with virtual CoV-PICS Visits - AIM|Acceptance with virtual CoV-PICS Visits - IAM|Acceptance with virtual CoV-PICS Visits - FIM|PICS Symptoms - Daily living|PICS Systems - Cognitive|PICS Systems - Nutrition|PICS Systems - PROMIS|PICS Symptoms - Memory","Washington University School of Medicine","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","202007053","September 29, 2020","July 30, 2021","July 30, 2021","July 29, 2020",,"October 5, 2020","Washington University School of Medicine/Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04490278"
287,"NCT03852537","Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia",,"Recruiting","No Results Available","Pneumonia","Drug: Methylprednisolone|Other: Usual Care","Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation|Mortality|Progression of disease|Evolution of respiratory failure|Evolution of kidney failure|Evolution of shock|Length of stay|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18-010925","December 2, 2019","July 2021","July 2022","February 25, 2019",,"April 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03852537"
288,"NCT04378803","Mindfulness Training for Seniors",,"Completed","No Results Available","Well Aging","Behavioral: Mindfulness training (MT) Connect","Change in mindfulness skills as measured by Five-Facet Mindfulness Questionnaire (5FMQ)|Change in mindfulness skills as measured by decentering - Experiences Questionnaire (EQ).|Change in psychological health as measured by Patient Health Questionnaire 4 items (PHQ4).|Change in positive affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in negative affect on psychological health as measured by the short variant of the Positive and Negative Affect Scale (PANAS).|Change in loneliness measured by the loneliness questions from the social isolation battery.|Change in loneliness measured by a loneliness question.|Change in attention|Change in well-being as measured by the Perseverative Thought Questionnaire (PTQ)|Change in well-being as measured by the Experience of Intrusions Scale (EIS)|Change in well-being as measured by the short version of the perceived stress scale (PSS).|Change in well-being as measured by the PERMA-Profiler","University of Miami","All","60 Years to 95 Years   (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20200443","May 13, 2020","August 4, 2020","August 4, 2020","May 7, 2020",,"August 17, 2020","University of Miami, Coral Gables, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04378803"
289,"NCT04418947","Project Resurgence Communication Trial",,"Completed","No Results Available","Communication Research","Other: Communication type","Percent with visit or procedure with provider|Percent with scheduled visit or procedure with provider|Percent with completed telemedicine visit with provider","University of Pennsylvania","All","Child, Adult, Older Adult","Not Applicable","11120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","843220","June 15, 2020","July 17, 2020","July 17, 2020","June 5, 2020",,"July 31, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04418947"
290,"NCT04505098","A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults","MITIGATE","Recruiting","No Results Available","Covid19|Atherosclerosis|Cardiovascular Diseases|Upper Respiratory Tract Infections","Drug: Icosapent ethyl","Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI","Kaiser Permanente|Amarin Corporation","All","50 Years and older   (Adult, Older Adult)","Phase 4","16500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1597940","August 7, 2020","August 7, 2021","February 28, 2023","August 10, 2020",,"October 5, 2020","Kaiser Permanente Northern California, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT04505098"
291,"NCT04148430","A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy",,"Recruiting","No Results Available","B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma","Drug: Anakinra","Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities|Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-168","October 30, 2019","October 2022","October 2022","November 1, 2019",,"August 24, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04148430"
292,"NCT04595695","The Effect of Clear Masks in Improving Patient Relationships",,"Recruiting","No Results Available","Communication|Trust|Covid19|Surgery","Behavioral: Transparent mask|Behavioral: Typical surgical covered mask","Patient Mask Preference Quantitative|Patient Mask Preference Qualitative|Patient Survey Scores Evaluating Surgeon Communication Skills|Patient Survey Scores Describing Trust in the Surgeon","University of North Carolina, Chapel Hill","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","20-2229","September 3, 2020","December 2020","December 2020","October 20, 2020",,"October 20, 2020","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04595695"
293,"NCT02332850","A Phase Ib Study of SAR650984 in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma",,"Suspended","No Results Available","Multiple Myeloma","Biological: Isatuximab|Drug: Carfilzomib|Drug: Dexamethasone|Drug: Lenalidomide","Incidence of adverse events (AE's) as measured by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version (v)4.03|Maximum tolerated dose of isatuximab|Pharmacokinetic (PK) profile of isatuximab|Overall response rate|Clinical benefit response|Overall survival (OS)|Progression Free Survival (PFS)|Time To Progression (TTP)|Duration of Response (DOR)|Incidence of isatuximab-specific antidrug antibodies|Percentage of bone marrow cells expressing cell surface determinant, CD38 and receptor density|Changes in pharmacodynamics variables as they relate to dose, response, and toxicity of carfilzomib in combination with isatuxima","Thomas Martin|University of California, San Francisco","All","up to 18 Years   (Child, Adult)","Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","139511|NCI-2015-00712","December 17, 2014","December 31, 2024","December 31, 2024","January 7, 2015",,"March 11, 2020","University of California, San Francisco, San Francisco, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02332850"
294,"NCT04401293","Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients",,"Recruiting","No Results Available","Sars-CoV2|COVID","Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin","Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.|Major bleeding|Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4|Sepsis-induced coagulopathy (SIC) score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization","Northwell Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20-0340","April 26, 2020","October 22, 2020","April 26, 2021","May 26, 2020",,"June 9, 2020","Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT04401293"
295,"NCT04439825","Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction",,"Not yet recruiting","No Results Available","Mood","Drug: Botulinum Neurotoxin|Drug: Placebo","Self- perception of mood before treatment and after achieving an optimal cosmetic result as determined by the PI.|Happiness levels before treatment and after achieving an optimal cosmetic result as determined by the PI.|Measurement of the Glabellar Wrinkle Severity Scores before treatment. The onset of effect and maximum efficacy compared to previous BOTOX Cosmetic injections will also be assessed by questionnaires.","DeNova Research","All","10 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BTX-PST-COVID","July 15, 2020","September 15, 2020","October 15, 2020","June 19, 2020",,"July 22, 2020","DeNova Research, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04439825"
296,"NCT04348370","BCG Vaccine for Health Care Workers as Defense Against COVID 19","BADAS","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Coronavirus as the Cause of Diseases Classified Elsewhere","Biological: BCG Vaccine|Biological: Placebo Vaccine","Incidence of COVID 19 Infection|Disease Severity","Texas A&M University|Baylor College of Medicine|M.D. Anderson Cancer Center|Cedars-Sinai Medical Center|Harvard University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","2020-0432F","April 20, 2020","May 2021","November 2021","April 16, 2020",,"May 27, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348370"
297,"NCT04504032","A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Rivaroxaban|Drug: Placebo","Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With AEs Leading to Study Discontinuation|Number of Participants With Serious Adverse Events (SAEs)|Proportion of Participants With Disease Progression|Median Time to Disease Resolution|Proportion of Participants Who Achieve Disease Resolution|Mean Gates Medical Research Institute Ordinal Scale Score|Change From Baseline in Gates Medical Research Institute Ordinal Scale Score|Mean World Health Organization Ordinal Scale Score|Change From Baseline in World Health Organization Ordinal Scale Score|Incidence of Hospitalization|Number of Days of Hospitalization","Bill & Melinda Gates Medical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gates MRI - COD-01-T01-01","September 2, 2020","December 2020","December 2020","August 7, 2020",,"October 6, 2020","Woodland Research Northwest LLC - ERG - PPDS, Rogers, Arkansas, United States|Science 37, Los Angeles, California, United States|Adult Medicine of Lake County, Mount Dora, Florida, United States|Providea Health Partners LLC, Evergreen Park, Illinois, United States|Clinical Research Institute, Inc - CRN - PPDS, Minneapolis, Minnesota, United States|South Texas Allergy and Asthma Medical Professionals, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04504032"
298,"NCT04308668","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","Completed","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Incidence of COVID19 Disease among those who are asymptomatic at baseline|Overall change in disease severity over 14 days among those who are symptomatic at baseline|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","1309","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MED-2020-28673","March 17, 2020","May 20, 2020","May 20, 2020","March 16, 2020",,"July 17, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04308668"
299,"NCT04574219","Virtual Parental Presence on Induction","VPPIA","Not yet recruiting","No Results Available","Anxiety|Surgery","Other: Use of Facetime with child and parents during induction","Virtual presence cause delays in operating room|Parent satisfaction with virtual presence|Operating room provider satisfaction|Operating room induction nurse satisfaction|Assessment of parental presence with either Facetime, Skype or Teams|Anxiety of child|Child behavior induction compliance|Parent anxiety|Patient previous induction experience|Parental Coaching - Prior|Parental Coaching - Day","Children's Hospital Medical Center, Cincinnati|The Hospital for Sick Children","All","4 Years to 12 Years   (Child)","Not Applicable","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2020-0371","October 2020","October 2022","December 2022","October 5, 2020",,"October 5, 2020","Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04574219"
300,"NCT04328961","Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)",,"Active, not recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","829","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00009750|INV-016204","March 31, 2020","September 30, 2020","October 31, 2020","April 1, 2020",,"September 7, 2020","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04328961"
301,"NCT04354428","Treatment for COVID-19 in High-Risk Adult Outpatients",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]","Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STUDY00009878|INV-017062","April 16, 2020","December 2020","January 2021","April 21, 2020",,"October 8, 2020","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","""Study Protocol: Hydroxychloroquine and Azithromycin arms"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_002.pdf|""Study Protocol: Lopinavir-Ritonavir arm"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_003.pdf|""Informed Consent Form: Hydroxychloroquine and Azithromycin arms"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_004.pdf|""Informed Consent Form: Lopinavir-Ritonavir arm"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_005.pdf","https://ClinicalTrials.gov/show/NCT04354428"
302,"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",,"Recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002011|Pro2020000712","April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336332"
303,"NCT04488081","I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","I-SPY_COVID","Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast","Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality","QuantumLeap Healthcare Collaborative|University of California, San Francisco|University of Pennsylvania|University of Minnesota|Emory University|University of Alabama at Birmingham|University of California, San Diego|University of Colorado, Denver|University of Southern California|Yale University|Columbia University|Wake Forest University Health Sciences|Sanford Health|Montefiore Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I-SPY-COVID","July 31, 2020","July 24, 2022","November 1, 2022","July 27, 2020",,"September 29, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04488081"
304,"NCT04497922","Virtual White Boards for Patient Satisfaction",,"Not yet recruiting","No Results Available","Satisfaction, Patient|Covid19|Emergencies|Satisfaction|Information Disclosure","Device: e-ink screen|Behavioral: Treatment as usual","emergency department satisfaction: likert scale|Quality of emergency department stay: likert scale|Preference for virtual white board","Brigham and Women's Hospital|E-ink corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020P002382","August 20, 2020","April 15, 2021","April 17, 2021","August 4, 2020",,"August 5, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04497922"
305,"NCT04344587","Awake Prone Position for Early Hypoxemia in COVID-19","APPEX-19","Enrolling by invitation","No Results Available","COVID-19","Other: Self-prone position recommendation|Other: Usual care","Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality","Boston University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-40070","April 23, 2020","December 2020","December 2020","April 14, 2020",,"September 24, 2020","Alvarado Hospital, San Diego, California, United States|St. Joseph's Hospital National Jewish Health, Denver, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Piedmont Atlanta, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Creighton University, Omaha, Nebraska, United States|Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas, United States|Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04344587"
306,"NCT04312009","Losartan for Patients With COVID-19 Requiring Hospitalization",,"Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15","University of Minnesota|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28675|INV-017069","April 13, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"July 21, 2020","University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|North Memorial Health Hospital, Robbinsdale, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04312009"
307,"NCT04381988","A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy",,"Recruiting","No Results Available","COVID-19|Cancer","Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy","cumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20-176","May 7, 2020","May 2021","May 2021","May 11, 2020",,"May 13, 2020","Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT04381988"
308,"NCT04348656","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","CONCOR-1","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)","Hamilton Health Sciences Corporation|Canadian Blood Services|Héma-Québec|University of Toronto|Université de Montréal|Weill Cornell Medicine/New York-Presbyterian|New York Blood Centre|McMaster University","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONCOR-1","May 14, 2020","October 31, 2020","December 31, 2020","April 16, 2020",,"October 20, 2020","Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Campbellton Regional Hospital, Campbellton, New Brunswick, Canada|Edmundston Regional Hospital, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada|Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada|Ciussse De L'Estrie CHUS, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT04348656"
309,"NCT04372589","Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )",,"Recruiting","No Results Available","COVID-19|Pneumonia","Drug: Heparin","Intubation and mortality|All-cause mortality|Intubation|Hospital-free days|ICU-free days|Ventilator-free days|Non-invasive ventilation|Organ support-free|Myocardial infarction|Ischaemic stroke|Venous thromboembolism|Major bleeding|Heparin-induced thrombocytopenia (HIT)","University of Manitoba|University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATTACC|OZM-113","May 20, 2020","January 2021","January 2021","May 4, 2020",,"June 4, 2020","University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Albany Medical College, Albany, New York, United States|Mount Sinai Health System, New York, New York, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of São Paulo, São Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Quebec-University Laval, Québec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04372589"
310,"NCT03944447","Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19","OMNI-Can","Recruiting","No Results Available","Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus","Drug: Cannabis, Medical","Prevention of COVID-19|Treatment of COVID-19|Treatment of Symptoms|Cannabis Impact on Quality of Life|Cannabis Route and Dosing|Monitoring Adverse Events","OMNI Medical Services, LLC|OMNI Medical Services Inc","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2","200000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00033337","December 1, 2018","December 31, 2025","December 31, 2025","May 9, 2019",,"August 28, 2020","OMNI Medical Services, Boca Raton, Florida, United States|OMNI Medical Services, Bradenton, Florida, United States|OMNI Medical Services, Fort Lauderdale, Florida, United States|OMNI Medical Services, Fort Myers, Florida, United States|OMNI Medical Services, Gainesville, Florida, United States|OMNI Medical Services, Merritt Island, Florida, United States|OMNI Medical Services, Miami, Florida, United States|OMNI Medical Services, Ocoee, Florida, United States|OMNI Medical Services, Pensacola, Florida, United States|OMNI Medical Services, Pompano Beach, Florida, United States|OMNI Medical Services, Tampa, Florida, United States|OMNI Medical Services, Wesley Chapel, Florida, United States|OMNI Medical Services, Beechwood, Ohio, United States|OMNI Medical Services, Bowling Green, Ohio, United States|OMNI Medical Services, Sandusky, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States|OMNI Medical Services, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03944447"
311,"NCT04422275","Coronavirus Smell Therapy for Anosmia Recovery","Co-STAR","Not yet recruiting","No Results Available","Anosmia","Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil","University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).|Global Rating of Smell.|Global Rating of Smell Change.","Washington University School of Medicine","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PA-18-334","June 1, 2021","June 1, 2023","December 31, 2023","June 9, 2020",,"June 11, 2020","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04422275"
312,"NCT04323800","Convalescent Plasma to Stem Coronavirus (CSSC-001)","CSSC-001","Recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Efficacy of treatment at Day 28|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2|Cumulative incidence of disease severity","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00245634","June 10, 2020","December 31, 2022","January 2023","March 27, 2020",,"October 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Chinle Office, Chinle, Arizona, United States|University of Arizona, Phoenix, Tucson, Arizona, United States|University of Arizona, Tuscon, Tucson, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|University of California, Davis, Sacramento, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04323800"
313,"NCT04334148","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro00105274","April 22, 2020","October 2020","October 2020","April 6, 2020",,"August 25, 2020","Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of Florida Health Central Florida, Leesburg, Florida, United States|University of Miami Florida, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hospital for Special Surgery, New York, New York, United States|Columbia University, Irving Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04334148"
314,"NCT04421664","Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)",,"Terminated","No Results Available","Corona Virus Infection|SARS-CoV Infection|Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Ordinal Scale of COVID19 Disease Severity at 14 days|Incidence of Hospitalization|Incidence of COVID-19 related Death|Incidence of all-cause Death|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Overall change in disease severity over 14 days among those who are symptomatic at baseline","McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta|University of British Columbia|McMaster University|Lawson Health Research Institute|Eastern Health|University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-6549","March 25, 2020","August 17, 2020","August 17, 2020","June 9, 2020",,"September 22, 2020","University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Eastern Health, Saint John's, Newfoundland and Labrador, Canada|McMaster University, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04421664"
315,"NCT04333732","CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION","CROWN CORONA","Recruiting","No Results Available","COVID 19","Drug: MR or M-M-R II ® vaccine|Drug: Placebo","Symptomatic COVID-19|Severity of COVID-19 over the study period|Effectiveness of preventing/reducing SARS-CoV-2 infection","Washington University School of Medicine|COVID -19 Therapeutics Accelerator","All","18 Years and older   (Adult, Older Adult)","Phase 3","30000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","202004099|INV-017499","September 4, 2020","August 2021","August 2021","April 3, 2020",,"September 9, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Unity Health Toronto, Toronto, Ontario, Canada|University of Ghana Medical Centre, Accra, Greater Accra Region, Ghana|St James's Hospital, Dublin, Leinster, Ireland|Radboud University Medical Center, Nijmegen, Netherlands|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Infectious Diseases Institute Kampala, Uganda, Kampala, Uganda|University College London, London, United Kingdom|Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia|University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT04333732"
316,"NCT04351880","Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge",,"Recruiting","No Results Available","Heart Failure|Copd|Liver Failure|Covid19|Diabetes Mellitus|Cancer|End Stage Renal Disease","Other: Medically Tailored Meals","Anxiety and Depression measured through the Hospital Anxiety and Depression Scale|Functional Status measured through the Katz Activities of Daily Living Scale|Re-hospitalization and Emergency Department Visits","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","IRB-1556587","April 16, 2020","February 2021","July 2021","April 17, 2020",,"May 4, 2020","St Joseph's Hospital, Denver, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04351880"
317,"NCT04329897","Acceptance and Commitment Therapy Delivered by Automated Software Messaging",,"Completed","No Results Available","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Behavioral: Software Messaging","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","University of Iowa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201412701-1","April 5, 2020","May 15, 2020","June 1, 2020","April 1, 2020",,"July 16, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT04329897"
318,"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Biological: Convalescent plasma|Other: Protocolised mechanical ventilation strategy|Drug: Eritoran|Drug: Apremilast|Drug: Aspirin|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor","All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome","MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 4","7100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","April 11, 2016","December 2021","December 2023","April 13, 2016",,"October 12, 2020","University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02735707"
319,"NCT04414826","Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness",,"Recruiting","No Results Available","Loneliness","Behavioral: Mindfulness Alone (MO) Intervention|Behavioral: Mindfulness + Compassion Intervention (MC)","Revised University of California Los Angeles Loneliness Scale - 8 (ULS-8)|Perceived Stress Scale (PSS)","University of Texas at Austin","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-04-0088","May 25, 2020","May 2021","May 2021","June 4, 2020",,"June 4, 2020","Laboratory for the Study of Anxiety Disorders, University of Texas at Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04414826"
320,"NCT01314066","Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)","VEGF-ARDS","Withdrawn","No Results Available","Severe Sepsis|Acute Respiratory Distress Syndrome","Drug: Bevacizumab|Drug: Placebo","Proportion of individuals progressing to meet RDS criteria as defined by the American- European ARDS consensus conference and as used by ARDSnet.|Ventilator-free days to Day 28|28 day all-cause mortality|Proportion of subjects progressing to acute lung injury (who do not meet the definition at randomization)|Worst PaO2/FiO2 ratio recorded following enrollment|Change in PaO2/FiO2 ratio between Day 0 to Day 3|Change from baseline in number of non-lung organ failures using the Multi-Organ Dysfunction (MOD) score and Sepsis Organ Failure Assessment (SOFA) score|Proportion of subjects surviving to hospital discharge|Vasopressor-free days|Reversal of shock if present at randomization.","Weill Medical College of Cornell University","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","IRB Protocol #0907010498","July 2010","November 2015","February 2016","March 14, 2011",,"May 3, 2016","Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01314066"
